

European Guideline on Chronic Pruritus

In cooperation with the European Dermatology Forum (EDF) and the European Academy of Dermatology and Venereology (EADV)

Elke WEISSHAAR¹, Jacek C. SZEPIETOWSKI², Ulf DARSOW³, Laurent MISERY⁴, Joanna WALLENGREN⁵, Thomas METTANG⁶, Uwe GIELER⁷, Torello LOTTI⁸, Julien LAMBERT⁹, Peter MAISEL¹⁰, Markus STREIT¹¹, Malcolm W. GREAVES¹², Andrew CARMICHAEL¹³, Erwin TSCHACHLER¹⁴, Johannes RING³ and Sonja STÄNDER¹⁵

¹Department of Clinical Social Medicine, Environmental and Occupational Dermatology, Ruprecht-Karls-University Heidelberg, Germany, ²Department of Dermatology, Venereology and Allergology, Wrocław Medical University, Poland, ³Department of Dermatology and Allergy Biederstein, Technical University München and ZAUM - Center for Allergy and Environment, Munich, Germany, ⁴Department of Dermatology, University Hospital Brest, France, ⁵Department of Dermatology, Lund University, Sweden, ⁶German Clinic for Diagnostics, Nephrology, Wiesbaden, ⁷Department of Psychosomatic Dermatology, Clinic for Psychosomatic Medicine, University of Giessen, Giessen, Germany, ⁸Department of Dermatology, University of Florence, Italy, ⁹Department of Dermatology, University of Antwerpen, Belgium, ¹⁰Department of General Medicine, University Hospital Muenster, Germany, ¹¹Department of Dermatology, Kantonsspital Aarau, Switzerland, ¹²Department of Dermatology, St. Thomas Hospital Lambeth, London, ¹³Department of Dermatology, James Cook University Hospital Middlesbrough, UK, ¹⁴Department of Dermatology, Medical University Vienna, Austria and ¹⁵Department of Dermatology, Competence Center for Pruritus, University Hospital Muenster, Germany

Corresponding addresses: Sonja Ständer M.D., Competence Center Chronic Pruritus, Department of Dermatology, University Hospital Münster, Von-Esmarch-Str. 58, DE-48149 Münster, Germany. E-mail: sonja.staender@uni-muenster.de

Elke Weisshaar M.D., Department of Clinical Social Medicine, Occupational and Environmental Dermatology, Ruprecht-Karls-University Heidelberg, Thibautstr. 3, DE-69115 Heidelberg, Germany. E-mail: elke.weisshaar@med.uni-heidelberg.de

Abbreviations and Explanations

AD:	Atopic dermatitis	PBC:	Primary biliary cirrhosis
AEP:	Atopic eruption of pregnancy	PEP:	Polymorphic eruption of pregnancy
CGRP:	Calcitonin gene-related peptide	PG:	Pemphigoid gestationis
CKD:	Chronic kidney disease	PN:	Prurigo nodularis
CP:	Chronic pruritus (longer than 6 weeks)	Pruritus:	A skin sensation which elicits the urge to scratch
DIF:	Direct immunofluorescence	PUO:	Pruritus of unknown origin
ICP:	Intrahepatic cholestasis of pregnancy	PTH:	Parathyroid hormone
IFSI:	International Forum on the Study of Itch	PV:	Polycythaemia vera
IIF:	Indirect immunofluorescence	RCT:	Randomised controlled trials
IL:	Interleukin	SSRI:	Selective serotonin re-uptake inhibitors
Itch:	Synonymous with pruritus	TRP:	Transient receptor potential
NSAID:	Non-steroidal anti-inflammatory drugs	UV:	Ultraviolet
PAR:	Proteinase-activated receptor	VIP:	Vasoactive intestinal peptide

1. The challenge of writing this guideline	3
2. Definitions and clinical classification	3
3. Epidemiology of chronic pruritus	3
4. The clinical picture of chronic pruritus	4
4.1 Pruritus in diseased conditions	4
4.1.1 Pruritus in inflamed skin and non-inflamed skin	4
4.1.2 Pruritus in kidney disease	4
4.1.3 Pruritus in hepatic diseases	4
4.1.4 Pruritus in metabolic and endocrine diseases	4
4.1.5 Pruritus in malignancies	4
4.1.6 Pruritus in infectious diseases	4
4.1.7 Pruritus in neurological diseases	5
4.1.8 Drug induced chronic pruritus	5
4.2 Specific patient populations	5
4.2.1 Chronic pruritus in the elderly	5
4.2.2 Chronic pruritus in pregnancy	6
4.2.3 Chronic pruritus in children	6
5. Diagnostic management	6
5.1 Patient's history, examination and clinical characteristics of pruritus	6
5.2 Diagnostic algorithm and Diagnostics	7
6. Therapy	7
6.1 General principles	7
6.2 Causative therapy and etiology specific treatment	9
6.3. Symptomatic therapy: topical	10
6.3.1 Local anaesthetics	10
6.3.2 Glucocorticosteroids	11
6.3.3. Capsaicin	11
6.3.4. Cannabinoid receptor agonists	12
6.3.5 Tacrolimus and Pimecrolimus	12
6.3.6 Acetylsalicylic Acid	12
6.3.8 Zinc, Menthol and Camphor	12
6.3.9 Mast cell inhibitors	12
6.4 Systemic therapy	13
6.4.1 Antihistamines	13
6.4.2 Mast cell inhibitors	13
6.4.3 Glucocorticosteroids	13
6.4.4 Opioid receptor agonists and antagonists	14
6.4.5 Gabapentin and Pregabalin	14
6.4.6 Antidepressants	14
6.4.7 Serotonin receptor antagonists	14
6.4.8 Thalidomide	15
6.4.9 Leukotriene receptor antagonist, TNF antagonists	15
6.4.10 Cyclosporin A	15
6.4.11 Aprepitant	15
6.5 UV phototherapy	15
6.6 Psychosomatic therapy (Relaxation techniques and psychotherapy)	16
7. Key summary of discussion concerning country-specific procedures	16
8. References	17

1. THE CHALLENGE OF WRITING THIS GUIDELINE

Chronic pruritus (CP) is a frequent symptom in the general population and in many skin and systemic diseases (1). Its frequency demonstrates a high burden and an impaired quality of life. This guideline addresses a symptom and not a disease. As a consequence of the diversity of possible underlying diseases, no single therapy concept can be recommended. Each form of pruritus has to be considered individually. There is still a significant lack of randomised controlled trials (RCT), that can be explained by the diversity and complexity of this symptom, multifactorial aetiologies of pruritus and the lack of well-defined outcome measures. To complicate matters, RCT exist for some types of pruritus, but with conflicting results. However, new therapies for improved medical care have been suggested. In addition, many expert recommendations are provided. The health care system in many countries and their social economic situation with constantly reducing financial resources increases the need for guidelines. These recommendations are based on a consensus of participating countries, while also allowing for country-specific treatment modalities, and health care structures. Furthermore, it should be appreciated that some topical and systemic therapies can only be prescribed “off-label” and require informed consent. If such “off-label” therapies cannot be initiated in the physician’s office, cooperation with a specialised centre for pruritus might be helpful.

This guideline addresses all medical disciplines that work with patients suffering from CP. This includes also entities defined by chronic scratch lesions such as prurigo nodularis and lichen simplex. The guidelines are not only focussed on dermatology.

2. DEFINITIONS AND CLINICAL CLASSIFICATION

The definitions presented in this guideline are based on a consensus among the European participants; however, some of them have provoked controversy. Most of the contributors accept pruritus and itch to be synonymous. A practical distinction is that between acute pruritus and chronic forms (lasting six weeks or longer). Pruritus/itch is a sensation that provokes the desire to scratch. According to the International Forum on the Study of Itch (IFSI), CP is defined as pruritus lasting 6 weeks or longer (2). Following the IFSI, the term “pruritus sine materia” will not be used in this guideline (3). In patients with no identified underlying disease, the term “pruritus of unknown origin” or “pruritus of undetermined origin” (PUO) is used. The term “pruritus of unknown aetiology” should be avoided as in most clinically well-defined forms of pruritus the mechanism is unknown (e.g. chronic kidney disease (CKD) associated pruritus). This guideline addresses patients

presenting with CP of different, including unknown, origin. If the underlying cause is detected, disease-specific guidelines should be consulted (e.g. atopic dermatitis (AD), cholestatic pruritus) (4–6).

According to the IFSI classification, the aetiology of CP is classified as I “dermatological”, II “systemic”, III “neurological”, IV “somatoform”, V “mixed origin” and VI “others” (2). The IFSI classification comprises a clinical distinction of patients with pruritus on primarily diseased/inflamed skin, pruritus on normal skin and pruritus with chronic secondary scratch lesions.

Somatoform pruritus is defined as pruritus where psychiatric and psychosomatic factors play a critical role in the initiation, intensity, aggravation or persistence of the pruritus. It is best diagnosed using positive and negative diagnostic criteria (5).

3. EPIDEMIOLOGY OF CHRONIC PRURITUS

Data on the prevalence of CP is very limited. The prevalence of CP seems to increase with age (7), but epidemiological studies are missing. It is estimated that about 60% of the elderly (≥ 65 years of age) suffer from mild to severe occasional pruritus each week (8), entitled senile pruritus or pruritus in the elderly. A population-based cross-sectional study in 19,000 adults showed that about 8–9% of the general population experienced acute pruritus, which was a dominant symptom across all age groups (9). Moreover, it was revealed that pruritus is strongly associated with chronic pain (10). Recent surveys indicate a point-prevalence of CP to be around 13.5% in the general adult population (11) and 16.8% in employees seeking detection cancer screenings (12). The 12-month prevalence of CP was 16.4% and its lifetime prevalence 22.0% in a German population-based cross-sectional study (11). All these data suggest a higher prevalence of CP in the general population than previously reported (11).

CP may be due to both dermatological and systemic diseases. However, the origin of pruritus is unknown in 8–15% of affected patients (1). The frequency of pruritus among patients with a primary rash depends on the skin disease. For example, pruritus is present in all patients with AD and urticaria (13), and about 80% of psoriatic patients (14, 15). Systemic diseases such as primary biliary cirrhosis (PBC) and CKD are associated with CP in 80–100% and 40–70%, respectively (16). In patients with Hodgkin’s lymphoma, pruritus is a frequent symptom, occurring in more than 30% of patients with Hodgkin’s disease.

Only few studies have addressed the frequency of pruritus in primary care. According to the Australian BEACH Program, a continuous national study of general practice activity, pruritus was the presenting complaint for 0.6% of consultations, excluding perianal, periorbital or auricular pruritus (17). In Britain, the

fourth national study of morbidity statistics from general practice (18) was conducted in 1991/1992 with 502,493 patients (1% sample of England and Wales), resulting in 468,042 person-years-at-risk. Pruritus and related conditions was present in 1.04% of consultations (male 0.73%, female 1.33%). On Crete, where patients with cutaneous disorders mostly present to hospitals rather than to primary care, PUO was diagnosed in 6.3% of 3,715 patients in 2003 (19).

4. THE CLINICAL PICTURE OF CHRONIC PRURITUS

4.1. Pruritus in diseased conditions

4.1.1. Pruritus in inflamed and non-inflamed skin. CP may occur as a common symptom in patients with dermatoses with primary skin lesions and systemic diseases without primary skin lesions. In systemic diseases, the skin may appear normal or have skin lesions induced by scratching or rubbing. In this case, a diagnosis might be difficult to establish. Systemic diseases frequently accompanied by pruritus are summarised in Table I. In some cases, pruritus may precede the diagnosis of the underlying disease by years. In the past years, several mechanisms of pruritus on inflamed and normal skin have been identified (see original version of EDF guideline, www.euroderm.org). In the following paragraphs some frequent patient populations and systemic diseases inducing CP are presented.

4.1.2. Pruritus in kidney disease. The pathophysiology of CKD-associated pruritus is unknown. Implicated mechanisms have included direct metabolic factors like increased concentrations of divalent ions (calcium, magnesium), parathyroid hormone (PTH), histamine and tryptase, dysfunction of peripheral or central nerves, the involvement of opioid receptors

(μ - and κ -receptors) and xerosis cutis (dry skin) have been suggested as likely candidates (20–28). New data point to a possible role of microinflammation that is quite frequent in uraemia (20, 29).

4.1.3. Pruritus in hepatic diseases. In patients with cholestasis due to mechanical obstruction, metabolic disorders or inflammatory diseases, CP is a frequent symptom (30). It may be quite severe and can even precede the diagnosis of e.g. PBC by years (31). In patients with infective liver disease (hepatitis B or C) or toxic liver disease (e.g. alcohol-induced), pruritus is less frequent. Hepatic pruritus is often generalised, affecting palms and soles in a characteristic way (32). One hypothesis for the mechanism of hepatic pruritus suggests that high opioid tone influences neurotransmission (30). Successful treatment with μ -receptor opioid antagonists such as nalmefene supports this hypothesis (33). It has recently been shown that increased serum autotaxin levels (enzyme that metabolizes lysophosphatidylcholine (LPC) into lysophosphatidic acid (LPA)) and thereby increased LPA levels are specific for pruritus of cholestasis, but not for other forms of systemic pruritus (34). Rifampicin significantly reduced itch intensity and ATX activity in pruritic patients. The beneficial antipruritic action of rifampicin may be explained partly by pregnane X receptor (PXR)-dependent transcription inhibition of ATX expression (34).

4.1.4. Pruritus in metabolic and endocrine diseases. In endocrine disorders as hyperthyroidism and diabetes mellitus, less than 10% of patients report pruritus (35, 36). In patients with hypothyroidism, pruritus is most probably driven by xerosis of the skin. Patients with primary hyperparathyroidism do complain about itch in a substantial number of cases (37). The pathophysiology of pruritus in primary hyperparathyroidism is not known. These patients often experience a lack of vitamin D and minerals (e.g. zinc, etc.) which probably contributes to CP.

Iron deficiency is frequently associated with pruritus (38). The mechanism for this is unknown. Iron overload as in hemochromatosis may lead to CP (39, 40).

4.1.5. Pruritus in malignancy. Several malignant disorders including tumours, bone marrow diseases and lymphoproliferative disorders may be accompanied by pruritus. In addition to toxic products generated by the tumour itself, allergic reactions to compounds released, and a direct affection on the brain or nerves (in brain tumours) may be the underlying mechanism (8, 41). In polycythemia vera (PV), more than 50% of patients suffer from pruritus (42, 43). Aquagenic pruritus with pinching sensations after contact with water is a characteristic but not necessary feature. It has been suggested that high levels of histamine released by the augmented numbers of basophilic granulocytes might trigger the itch (44). For PV this seems to be most pronounced in patients showing the JAK2 617V mutation (45).

Table I. Systemic diseases that can induce pruritus (examples)

Metabolic and endocrine diseases	<ul style="list-style-type: none"> • Chronic renal insufficiency • Liver diseases with or without cholestasis • Hyperparathyroidism • Hyper- and hypothyroidism • Iron deficiency
Infective diseases	<ul style="list-style-type: none"> • HIV and AIDS • Parasitoses including Helminthosis
Haematological disorders	<ul style="list-style-type: none"> • Polycythemia vera, myelodysplastic syndrome • Lymphoma, e.g. Hodgkin lymphoma
Neurological diseases	<ul style="list-style-type: none"> • Multiple sclerosis • Brain tumours • Notalgia paresthetica • Brachioradial pruritus • Postzosteric neuralgia
Psychiatric or psychosomatic diseases	<ul style="list-style-type: none"> • Depression • Affective disorders • Hallucinosi • Obsessive and compulsory disorders • Schizophrenia • Eating disorders

Pruritus in Hodgkin's disease often starts on the legs and is most severe at night, but generalised pruritus soon ensues. Several factors such as secretion of leukopeptidases and bradykinine, histamine release and high IgE levels with cutaneous depositions may contribute to pruritus in lymphoma (46). Patients with carcinoid syndrome may experience pruritus in addition to flushing, diarrhoea and cardiac symptoms (47).

4.1.6. Pruritus in infectious diseases. Some generalised infections are accompanied by pruritus. Above all, patients infected with HIV may develop a pruritic papular eruption or eosinophilic folliculitis. These entities are easily diagnosed by inspection and histology of the skin and have a high positive predictive value (48, 49).

Whether toxocara infections lead to pruritus in a substantial number of patients remains to be confirmed (50).

4.1.7. Pruritus in neurological diseases. Multiple sclerosis, brain infarction and brain tumours are rarely accompanied by pruritus (51, 52). Localised pruritus suggests a neurological origin such as compression of the peripheral or central afferences. This neuropathic origin of localised CP can be found e.g. in postzoster pruritus, notalgia paraesthetica and brachioradial pruritus, where an underlying spinal damage is likely (53–56).

4.1.8. Drug induced chronic pruritus. Almost every drug may induce pruritus by various pathomechanisms (Table II) (57). Some may cause urticarial or morbilliform ras-

hes presenting with acute pruritus. Furthermore, drug-induced hepatotoxicity or cholestasis as well as drugs leading to xerosis or phototoxicity may produce CP on normal skin (58). Hydroxyethyl starch, a compound used for fluid restoration, can induce chronic generalised or localised pruritus (59).

4.2. Specific patient populations

4.2.1. Chronic pruritus in the elderly. Only a small number of studies have investigated pruritus in the elderly. They are characterised by selection bias and differing end points (pruritic skin disease or itch). An American study of cutaneous complaints in the elderly identified pruritus as the most frequent, accounting for 29% of all complaints (60). A Turkish study in 4,099 elderly patients found that pruritus was the commonest skin symptom with 11.5% affected. Women were more frequently affected (12.0%) than men (11.2%). Patients older than 85 years showed the highest prevalence (19.5%) and pruritus was present more frequently in winter months (12.8%) (61). In a Thai study, pruritic diseases were the most common skin complaint (41%) among the elderly, while xerosis was identified as the most frequent ailment (38.9%) in a total of 149 elderly patients (62). The exact mechanisms of CP in the elderly are unknown. Pathophysiological changes of the aged skin, decreased function of the stratum corneum, xerosis cutis, co-morbidities and polypharmacy may all contribute to its aetiology (63).

Table II. Drugs that may induce or maintain chronic pruritus (without a rash)

Class of drug	Substance (examples)
ACE inhibitors	Captopril, enalapril, lisinopril
Antiarrhythmic agents	Amiodarone, disopyramide, flecainide
Antibiotics	Amoxicillin, ampicillin, cefotaxime, ceftriaxone, chloramphenicol, ciprofloxacin, clarithromycin, clindamycin, cotrimoxazole, erythromycin, gentamycin, metronidazole, minocycline, ofloxacin, penicillin, tetracycline
Antidepressants	Amitriptylin, citalopram, clomipramin, desipramine, doxepin, fluoxetine, fluvoxamine, imipramine, lithium, maprotiline, mirtazapine, nortriptyline, paroxetine, sertraline
Antidiabetic drugs	Glimepiride, metformin, tolbutamide
Antihypertensive drugs	Clonidine, doxazosin, hydralazine, methyldopa, minoxidil, prazosin, reserpine
Anticonvulsants	Carbamazepine, clonazepam, gabapentin, lamotrigine, phenobarbital, phenytoin, topiramate, valproic acid
Anti-inflammatory drugs	Acetylsalicylic acid, celecoxib, diclofenac, ibuprofen, indometacin, ketoprofen, naproxen, piroxicam
AT II antagonists	Irbesartan, telmisartan, valsartan
Beta blockers	Acebutolol, atenolol, bisoprolol, metoprolol, nadolol, pindolol, propranolol
Bronchodilators, mucolytic agents, respiratory stimulans	Aminophylline, doxapram, ipratropium bromide, salmeterol, terbutaline
Calcium antagonists	Amlodipine, diltiazem, felodipine, isradipine, nifedipine, nimodipine, nisoldipine, verapamil
Diuretics	Amiloride, furosemide, hydrochlorothiazide, spironolactone, triamterene
Hormones	Clomifene, danazol, oral contraceptives, estrogens, progesterone, steroids, testosterone and derivatives, tamoxifen
Immunosuppressive drugs	Cyclophosphamide, cyclosporine, methotrexate, mycophenolatmofetil, tacrolimus (up to 36%), thalidomide
Antilipids	Clofibrate, fenofibrate, fluvastatin, lovastatin, pravastatin, simvastatin
Neuroleptics	Chlorpromazine, haloperidol, risperidone
Plasma expanders, blood supplying drugs	Hydroxyethyl starch, pentoxifylline
Tranquilizers	Alprazolam, chlordiazepoxide, lorazepam, oxazepam, prazepam
Uricostatics	Allopurinol, colchicine, probenecid, tiopronin

4.2.2. Chronic pruritus in pregnancy. There are no epidemiological studies assessing the prevalence of CP in pregnancy. Pruritus is the leading dermatological symptom in pregnancy estimated to occur in about 18% of pregnancies (64). Pruritus is the leading symptom of the specific dermatoses of pregnancy such as polymorphic eruption of pregnancy (PEP), pemphigoid gestationis (PG), intrahepatic cholestasis of pregnancy (ICP), atopic eruption of pregnancy (AEP), but may also occur in other dermatoses coinciding by chance with pregnancy or in pre-existing dermatoses (64–67). PEP is one of the most common gestational dermatoses, affecting about one in 160 pregnancies. While PG, PEP and ICP characteristically present in late pregnancy, AEP starts in 75% of cases before the third trimester (1, 65, 68).

ICP is characterised by severe pruritus without any primary skin lesions, but secondary skin lesions occur due to scratching. It is more prevalent among native Indians in Chile (27.6%) and Bolivia (13.8%) depending on ethnic predisposition and dietary factors (68, 69). ICP has decreased in both countries, e.g. to 14% in Chile. ICP is more common in women of advanced maternal age, multiple gestations, personal history of cholestasis on oral contraceptives and during winter months. Scandinavian and Baltic countries are also more affected (1–2%). In Western Europe and North America, ICP is observed in 0.4–1% of pregnancies (68–70).

The use of topical and systemic treatments depends on the underlying aetiology of pruritus and the stage and status of the skin. Because of potential effects on the foetus, the treatment of pruritus in pregnancy requires prudent consideration of whether the severity of the underlying disease warrants treatment and selection of the safest treatments available. Systemic treatments such as systemic glucocorticosteroids, a restricted number of antihistamines and ultraviolet phototherapy, e.g. UVA, may be necessary in severe and generalised forms of CP in pregnancy.

4.2.3. Chronic pruritus in children. There are no epidemiological studies assessing the prevalence of CP in children (1, 64). Differential diagnosis of CP in children has a wide spectrum (64) but is dominated by AD. The cumulative prevalence of AD is between 5 to 22% in developed countries. The German Atopic Dermatitis Intervention Study (GADIS) showed a significant correlation between the pruritus intensity and severity of AD and sleeplessness (71, 72). A Norwegian cross-sectional questionnaire-based population study in adolescents revealed a pruritus prevalence of 8.8%. Pruritus was associated with mental distress, gender, sociodemographic factors, asthma, rhinoconjunctivitis and eczema (73). Itching of mild to moderate severity may occur in acne (74, 75).

There are no studies about systemic causes of CP among children. It must be assumed that systemic causes in children are mostly based on genetic diseases or

systemic diseases, e.g. biliary atresia or hypoplasia, familial hyperbilirubinemia syndromes, polycystic kidney disease. Drug-induced pruritus without any specific skin symptoms appears to be rare in children (1). Common medications associated with CP in adults play a minor role in children due to limited use at that age.

When considering treatment, the physician must remember that topically applied drugs may cause intoxication due to the different body volume/body surface area rate. In addition, the licensed age for the drug must be taken into account. Low- (class 1, 2) to medium-strength (class 3) glucocorticosteroids may be applied in children. Topical immunomodulators are used for AD and pruritus in children ≥ 2 years, but in some European countries e.g. pimecrolimus is licensed for use in children > 3 months. Topical capsaicin is not used in children < 10 years. The dosages of systemic drugs need to be adapted in children. Ultraviolet phototherapy should be performed with caution due to possible long-term photodamage of the skin.

5. DIAGNOSTIC MANAGEMENT

5.1. Patient's history, examination and clinical characteristics of pruritus

The collection of the patient's history and a thorough clinical examination are crucial at the first visit, as it forms an assessment of their pruritus including intensity, onset, time course, quality, localisation, triggering factors and the patient's theory of causality. Attention should be paid to incidents preceding or accompanying the onset of pruritus (e.g. pruritus following bathing). It is also important to consider the methods used to relieve pruritus, e.g. brushes. This helps with the interpretation of clinical findings such as the absence of secondary skin lesions in the mid-back known as the "butterfly sign" that indicates that the patient cannot reach this area by hand and is thus unable to scratch it. It is also important to ask about preexisting diseases, allergies, atopic diathesis and drug intake (Table II). A great deal of helpful information can be obtained using questionnaires. There are no definite clinical findings related to specific pruritic diseases (76), but awareness of the following anamnestic aspects and clinical findings may help with the diagnosis of the cause of pruritus:

- When several family members are affected, scabies or other parasites should be considered.
- The relationship between pruritus and special activities is important: Pruritus during physical activity is suggestive of cholinergic pruritus. It is common in patients with atopic eczema and mild forms of cholinergic pruritus. Pruritus provoked by skin cooling after bathing should prompt consideration of aquagenic pruritus. It may be associated with or precede PV or myelodysplastic syndrome, and

screening for these diseases should be performed intermittently.

- Nocturnal generalised pruritus associated with chills, fatigue, tiredness and “B” symptoms (weight loss, fever and nocturnal sweating) raises the possibility of Hodgkin’s disease.
- Somatoform pruritus rarely disturbs sleep; most other pruritic diseases cause nocturnal wakening.
- Seasonal pruritus frequently presents as “winter itch”, which may also be the manifestation of pruritus in the elderly due to xerosis cutis and asteatotic eczema.

A patient’s history should always include all current and recent medications, infusions, and blood transfusions. Severe pruritus can lead to considerable psychological distress. This should not be underestimated by the physician and should be addressed directly. CP can be accompanied by behavioural/adjustment disorder and a withdrawal from social and work life (77). In these cases, psychosomatic counselling is required. CP with excoriations sometimes progressing to self-mutilation can be caused by psychiatric disease such as delusional parasitosis. Such patients need psychiatric examination and if necessary treatment. A solely psychological cause of pruritus should not be diagnosed without psychiatric examination.

Examination of patients with CP includes a thorough inspection of the entire skin including mucous membranes, scalp, hair, nails, and anogenital region. The distribution of primary and secondary skin lesions should be recorded together with skin signs of systemic disease. General physical examination should include palpation of the liver, kidneys, spleen, and lymph nodes.

There is no standardised method of documenting pruritus. The sensation of pruritus is subject to much inter- and intra-individual variation due to tiredness, anxiety, stress. Questionnaires deliver self-reported information regarding various aspects of CP. So far, no structured questionnaire exists, but the questionnaire should consider the patients’ perspective, the medical doctors’ perspective and needs of various measurements of clinical trials. Several different questionnaires in different languages for different pruritic diseases have been developed, but so far no definite questionnaires exist. Additional tools are needed to better assess the different dimensions of CP and better tailor management. With this goal in mind, a special interest group (SIG) was initiated by members of the IFSI to determine which of the various psychometric properties of CP questionnaires offer the greatest utility in the evaluation of CP (78). The intensity of pruritus is usually assessed by scales such as the visual analogue scale (VAS) or the numeric rating scale (79, 80). When using a VAS, the scale ranges from 0–10 and is graphically presented as a bar chart. However, these methods often fail to consider the frequency of itch attacks over the course of a day. For patients with severe PUO, it can be helpful to keep a diary in order to allow for clearer attribution of the symptoms.

5.2. Diagnostic algorithm and diagnostics

Laboratory screening, clinical and technical approaches and investigations are summarised in Table III and IV. All this helps to follow a diagnostic algorithm (Fig. 1).

6. THERAPY

6.1. General principles

In the patient with CP it is important to establish an individual therapy regimen according to their age, pre-existing diseases, medications, quality and intensity of pruritus. Most importantly, elderly patients, pregnant women and children need special attention. As the care of patients with CP often extends over a long period, with initial uncertainty about the origin of their pruritus, frustration regarding the failure of past therapies and general psychological stress frequently occurs. The diagnostic procedures and therapy should be discussed with the patient in order to achieve best possible concordance and compliance. It must be remembered that some therapies are not licensed for CP and can only be prescribed “off-label”. This requires separate informed consent.

Table III. *Diagnostics: laboratory screening, diverse approaches and investigations*

Chronic pruritus: First-step lab screening	Differential blood cell count, ESR Blood urea nitrogen, creatinine Alkaline phosphatase, liver enzymes Bilirubine T3, T4, TSH Glucose Serum iron, Ferritin Age > 40 years: stool occult blood
Chronic pruritus: further investigations	Immunelectrophoresis Hepatitis serology, Cholesterol, Triglycerides Parathormone Erythrocyte-Fluorescence (EPP) Biopsy with DIF (mastocytosis, pemphigoid etc.) Swab for candida (mucocutaneous pruritus) Urine: mast cell metabolites Further imaging studies and bone marrow investigation for mastocytosis
Chronic pruritus: approach I	Detailed history: preceding skin changes? Weight loss, fever, fatigue Emotional stress? Medication? Drug abuse? Subtle primary skin disorders: xerosis, scabies Physical examination Bath oil, emollient/education Follow-up appointment in 2 weeks
Chronic pruritus: approach II	Detailed history renewed Lab screening (see above and Table IV) Detailed general physical examination: LN, rectal Stool for parasites Chest X-ray Biopsy Complete internist work-up, further imaging Follow-up

Table IV. Laboratory and technical investigations in chronic pruritus due to systemic diseases

Laboratory and technical screening-basic	Creatinine, AST, ALT, alkaline phosphatase, bilirubin, TSH, complete blood count, glucose, chest X-ray, (Ca, y-GT, stool test for parasites in genito-anal pruritus)
<i>Metabolic and endocrine diseases</i>	
Renal insufficiency	Lab I: Creatinine, (and urea for elderly) Lab II: phosphate, PTH, HCO ₃ , urinalysis, urine protein concentration. ANA, anti-ds-DNS-Ab, ANCA, Anti-GBM-Ab etc. Tech: sonography of the kidneys, CT or MRI
Liver diseases with or without cholestasis	Lab I: y-GT, AP, bilirubin, AST, ALT, (and HB-, HC-antibodies, if a risk-patient) Lab II: LDH, AMA, ANA, Anti-HBc-Ab, HBs-Ag, Anti-HCV-Ab, anti-smooth muscle Ab, antiactin Ab Tech: sonography of the liver, CT or MRT, (Magnetic resonance cholangiogram (MRC) or endoscopic retrograde cholangiogram (ERC) to rule out primary sclerosing cholangitis)
Hyperparathyroidism	Lab I: PTH, Calcium (only, if symptoms or signs of hyperparathyroidism (“stones, bones, moans and abdominal groans and psychiatric overtones”)) Lab II: phosphate, Vit D (1,25-Vit D, 25 Vit-D) Tech: sonography of the parathyroid glands, scintigraphy, MRI
Hyper- and hypothyroidism	Lab I: TSH, Lab II: T3, T4, MAKs and TRAKs Tech: sonography of the thyroid glands, Iodine-scintigraphy
Anemia	Lab I: complete blood count including MCV and MCHC, LDH Lab II: ferritin, transferrin saturation (TSAT) – optionally: Lab III: Bone marrow aspiration with iron staining
Iron deficiency	Lab I: ferritin Lab II: transferrin saturation (TSAT)
Malabsorption	(Lab-tests only in case of a typical history (pancreas disease, intestinal resection) or symptoms like chronic diarrhea or steatorrhea and weight loss.) Lab I: Serum protein, serum albumine, calcium, blood count, gliadin-antibody Lab II: Vitamin A (hyperkeratosis by Vitamin A deficiency), Vitamin B12 (neuropathy by Vitamin B deficiency) Tech: endoscopy with biopsy
<i>Other diseases</i>	
Pruritus of the elderly	Lab I: Lab screening: creatinine, ALT, AST, alkaline phosphatase, bilirubin, TSH, full blood count, + BUN, (+ estimated creatinine clearance)
Infective diseases	HIV: HIV-antibodies, Westernblot Parasitoses including Helminthosis, Giardia lamblia (rare): stool culture and microscopic examination
Haematological disorders	Polycythemia vera: Lab I: blood count, thrombocytes, sedimentation rate Lab II: to rule out secondary erythrocytosis: O ₂ saturation, erythropoietin (EPO) level (renal cell carcinoma or polycystic kidneys) Lab III: bone marrow with chromosomal aberrations, Tech: sonography, CT or MRI of the spleen, Lymphoma: Lab I: blood count, blood smear, thrombocytes, sedimentation rate, Lab II: Bone marrow with chromosomal aberrations, Tech: sonography, CT or MRI of the abdomen, thorax and additional affected areas, (PET)
Neurological diseases	Multiple sclerosis: Lab: cerebrospinal fluid analysis (oligoclonal bands?) Tech: EEG, MRI, CT of the brain and functional tests Brain tumours: Lab: cerebrospinal fluid analysis with histopathology Tech: EEG, MRI, CT of the brain Notalgia paresthetica: MRI of the thoracic spine Brachioradial pruritus: MRI of the thoracic and cervical spine
<i>Psychiatric or psychosomatic diseases</i>	Psychiatric and psychosomatic exploration, psychiatric short questionnaire for depressive and anxiety disorder
Pregnancy with or without cholestasis	Lab I: y-GT, AP, bilirubin, AST, ALT, bile acids Lab II: Virus screen: hepatitis A, B, C, Epstein Barr and cytomegalovirus, a liver autoimmune screen for chronic active hepatitis and primary biliary cirrhosis (anti-smooth muscle and antimitochondrial antibodies) (67) Tech: liver ultrasound
Drug induced pruritus	Lab I: y-GT, AP, bilirubin, AST, ALT, LDH Skin biopsy in case of HES exposition (electron microscopy)




Fig. 1. Diagnostic algorithm.

First, the patient should be informed about general pruritus-relieving measures (Table V). They include simple and helpful measures such as wet and cold wraps, application of lotio alba, etc. Application of short-time localised heat has shown promising itch-relieving results in case reports and an experimental study (81). Prior to further symptomatic therapy, the patient should be subject to a careful diagnostic evaluation and therapy given for any underlying disease (see Tables III, IV). If pruritus still persists, combined or consecutive step-by-step symptomatic treatment is necessary (Table VI). Pharmacologic interventions for specific pruritic diseases, e.g. urticaria should be performed according to the guideline of the specific disease and the field’s Cochrane Group (82, 83).

6.2. Causative therapy and aetiology specific treatment

CP can be addressed by treating the underlying disease. Therapeutic measures include specific treatments of underlying dermatoses, avoidance of contact allergens, discontinuation of implicated drugs, specific internal, neurological and psychiatric therapies, surgical treatment of an underlying tumour or transplantation of organs. Normally, there is sudden relief of pruritus when the underlying disease improves, e.g. when Hodgkin’s disease responds to chemotherapy or when a patient with PBC has been transplanted. For some underlying diseases, specific treatments have proven to be successful in relieving pruritus, even if the underlying disease is

Table V. General measures for treating chronic pruritus

Avoidance of	Factors that foster dryness of the skin, as e.g. dry climate, heat (e.g. sauna), alcoholic compresses, ice packs, frequent washing and bathing Contact with irritant substances (e.g. compresses with rivanol, chamomile, tea-tree oil) Very hot and spicy food, large amounts of hot drinks and alcohol Excitement, strain, negative stress In atopic patients: avoidance of aerogen allergens (e.g. house dust and house dust mites) which may aggravate pruritus
Application of	Mild, non-alkaline soaps, moisturizing syndets and shower/bathing oils Luke-warm water, bathing time not exceeding 20 min In patients with dermatoses: after contact with water, the skin should be dabbed dry without rubbing, because damaged and inflamed skin might worsen Soft clothing permeable to air, e.g. cotton, silver-based textiles Skin moisturizer on a daily basis especially after showering and bathing Topicals with symptomatic relief especially for pruritus at night: creams/lotions/sprays with e.g. urea, campher, menthol, polidocanol, tannin preparations Wet, cooling or fat-moist-wrappings, wrappings with black tea, short and lukewarm showers
Relaxation techniques	Autogenic training, relaxation therapy, psychosocial education
Education	Coping with the vicious circle of itch–scratch–itch Educational training programs e.g. for children suffering from atopic dermatitis or chronic pruritus (71, 72, 254)

Table VI. Stepwise symptomatic-therapeutic approach in chronic pruritus (>6 weeks)

	Therapy
Step 1	<ul style="list-style-type: none"> • General therapeutic measures (Table V), especially basic therapy with moisturizers • Initial symptomatic therapy: systemic H1 antihistaminics*, topical corticosteroids
Step 2	<ul style="list-style-type: none"> • Symptomatic causative adapted therapy (Fig. 1, Tables 5, 7–9) if origin is unknown
Step 3	<ul style="list-style-type: none"> • In pruritus of unknown origin or therapy refractory cases in the 2nd step: symptomatic topical and/or systemic therapy, e.g. capsaicin, calcineurin inhibitors, cannabinoid agonists, naltrexone, gabapentin, UV phototherapy, immunosuppressives (cyclosporine)
Concomitant treatment in every step	<ul style="list-style-type: none"> • Diagnostics and treatment of underlying disease • General therapeutic measures (Table V) • In sleep disorders: sedative H1-antihistaminics, tranquilizers, tricyclic antidepressants or neuroleptics • Psychosomatic care, behavioural therapy for scratch behaviour • In erosive scratch lesions: disinfecting measures, topical corticosteroids

*There is no evidence for the following diagnoses: cholestatic pruritus, nephrogenic pruritus

not treated. Aetiology specific treatments act on a known or hypothetically assumed pathogenesis of pruritus in underlying diseases. For only a few of these treatments evidence of efficacy can be found in controlled studies. Treatments for CP in specific diseases are presented in Tables VII–XI. When deciding the choice of treatment, consideration should be given to the level of evidence, side-effects, practicability, costs, availability of a treatment and individual factors such as patient's age.

6.3. Symptomatic therapy: topical

6.3.1. Local anaesthetics. Local anaesthetics act via different groups of skin receptors. They can be used for pain, dysaesthesia and pruritus. Benzocaine, lidocaine, pramoxine as well as a mixture of prilocaine and lidocaine are widely used topically, but have only a short-term effect. In experimental studies, the antipruritic effect of local anaesthetics is limited in diseased skin, e.g. AD (84, 85). Successful application in the treatment of loca-

Table VIII. Therapeutic options in hepatic and cholestatic pruritus

Antipruritic effects confirmed in controlled studies	<ul style="list-style-type: none"> • Cholestyramine 4–16 g/day (not in primarily biliary cirrhosis!) (31) • Ursodesoxycholic acid 13–15 mg/kg/day (264) • Rifampicin 300–600 mg/day (265) (Kremer, van Dijk 2012) • Naltrexone 50 mg/day (159, 266) • Naloxone 0.2 µg/kg/min (156) • Nalmefene 20 mg 2×/day (157) • Sertraline 75–100 mg/day (187) • Thalidomide 100 mg/day (267)
Equivocal effects in controlled studies	<ul style="list-style-type: none"> • Ondansetron 4 mg or 8 mg i.v. or 8 mg orally (189, 190, 195, 196)
Antipruritic effects confirmed in case reports	<ul style="list-style-type: none"> • Phenobarbital 2–5 mg/kg/day (268) • Stanozolol 5 mg/day (269) • Phototherapy: UVA, UVB (270) • Bright light therapy (10.000 Lux) reflected toward the eyes up to 60 min twice/day (271) • Etanercept 25 mg sc. 2×/week (272) • Plasma perfusion (270) • Extracorporeal albumin dialysis with Molecular Adsorbent Recirculating System (MARS) (273–278) • Liver transplantation (279)

Table VII. Therapeutic options in chronic kidney disease-associated pruritus

Antipruritic effects confirmed in controlled studies	<ul style="list-style-type: none"> • Activated charcoal 6 g/day (41) • Gabapentin 300 mg 3×/week postdialysis (170) • Gamma-linolenic acid cream 3×/day (261) • Capsaicin 3–5×/day (98, 99) • UVB phototherapy (237) • Acupuncture at the Quchi (L111) acupoint (262) • Nalfurafine intravenously postdialysis (25) • Thalidomide 100 mg/day (211)
Equivocal effects in controlled studies	<ul style="list-style-type: none"> • Naltrexone 50 mg/day (26, 27) • Ondansetron 8 mg orally or i.v. (202, 203)
Antipruritic effects confirmed in case reports	<ul style="list-style-type: none"> • Cholestyramine (41) • Tacrolimus ointment 2×/day (124, 125) • Cream containing structured physiological lipids with endocannabinoids (110) • Mirtazapine (179) • Cromolyn sodium (151) • Erythropoietin 36 IU/kg 3×/week (263) • Lidocaine 200 mg i.v./day (41) • Ketotifen 1–2 mg/day (150)

Table IX. Antipruritic therapy of atopic dermatitis*

Antipruritic effects confirmed in controlled studies	<ul style="list-style-type: none"> • Glucocorticosteroids (topical and oral) • Cyclosporin A • Leukotriene antagonists (e.g. zafirlukast) • Interferon-gamma, i.c. • Tacrolimus ointment (2×/day) • Pimecrolimus cream (2×/day) • Doxepin 5% cream (2×/day) (131, 132)
Equivocal results:	<ul style="list-style-type: none"> • Antihistamines (topical and systemic) • Naltrexon 50 mg/day (281) • Mycophenolatemofetil
Antipruritic effects confirmed in case reports	<ul style="list-style-type: none"> • Antipruritic effects confirmed in case reports: • Macrolide antibiotics • Immunoglobuline, i.v. • UVA1-/UVB 311-Therapie • Capsaicin (3–5×/day)

*We refer to the current guideline for atopic dermatitis and ref. 280.

Table X. *Therapeutic options in polycythaemia vera*

Effects confirmed in case reports
<ul style="list-style-type: none"> • Paroxetine 20 mg/day (42, 181) • Hydroxyzine (42) • Fluoxetine 10 mg/day (181) • Aspirin (282) • Cimetidine 900 mg/day (283, 284) • Pizotifen 0.5 mg 3×/day (285) • Cholestyramine (286) • Ultraviolet B phototherapy (241) • Photochemotherapy (PUVA) (287, 288) • Transcutaneous electrical nerve stimulation (289) • Interferon-alpha (290–293)

lised forms of pruritus such as notalgia paraesthetica has been reported (85, 86). When treating larger skin areas, polidocanol 2–10% in different galenic formulations can be used, frequently in combination with 3% urea. There are no controlled clinical trials investigating the antipruritic effects of local anaesthetics.

Expert recommendation: Short term application of topical local anaesthetics can be recommended as an additional therapy. The risk of sensitization can be considered as low.

6.3.2. Glucocorticosteroids. Pruritus experimentally induced by histamine was significantly suppressed by topical hydrocortisone when compared to placebo (87). All other clinical studies apply to an underlying inflammatory dermatosis in which "pruritus" was one parameter amongst many. Clinical experience shows that topical glucocorticosteroids can be effective if itch is the consequence of an inflammatory dermatosis. Use of topical glucocorticosteroids to treat the symptom of pruritus is not advised in the absence of an inflammatory dermatosis. Topical glucocorticosteroids with a favourable side-effect profile (e.g. fluticasone propionate, methylprednisolone aceponate or mometasone furoate)

Table XI. *Therapeutic options in aquagenic pruritus*

Effects confirmed in case reports (294–296)
<ul style="list-style-type: none"> • Topical capsaicin 0.025–1% thrice/day for 4 weeks • Glycerol trinitrate topically 2% • Transdermal application of scopolamine, topically 3 or 9% • Baths with sodium bicarbonate (0.5–1 kg/bath) • Bath and systemic PUVA, UVB (242–245) • Propranolol 10 to 80 mg/day • Clonidine 0.1 mg twice/day • Astemizol 10 mg/day • Ibuprofen (prior to bathing) • Pregabalin 150–300 mg/day • Antihistamines, e. g. hydroxyzine 25 mg/day, chlorpheniramine 8 mg/day, cetirizine, loratadine, fexofenadine, terfenadine • H₂-blockers: cimetidine 900 mg/day • Opioid receptor antagonists, e. g. naltrexone 25–50 mg/day • Selective serotonin reuptake inhibitors, e. g. paroxetine 20 mg/day, fluoxetine 10 mg/day • Interferon-alpha 2b 5×3 mil IE 1st week, 3×3 mil IE 2nd – 4th week
Effects confirmed in RCT
<ul style="list-style-type: none"> • Acetylic salicylic acid 300–500 mg/day

are to be preferred (88, 89). In some cases the anti-inflammatory effect of glucocorticosteroids is helpful, but insufficient to completely abolish pruritus (90).

Expert recommendation: Initial short-term application of topical glucocorticosteroids can be recommended in CP associated with an inflammatory dermatosis, but should not be used as long-term treatment or in the absence of a primary rash.

6.3.3. Capsaicin. Capsaicin (trans-8-methyl-N-vanillyl-6-nonenamide) is the pungent agent of chilli peppers and is used as a pain-relieving medication (91). Topical application of capsaicin activates sensory C-fibres to release neurotransmitters inducing dose-dependent erythema and burning. After repeated applications of capsaicin, the burning fades due to tachyphylaxis and retraction of epidermal nerve fibres (91). However, pruritus reoccurs some weeks after discontinuation of therapy indicating no permanent degeneration of the nerve fibres (92).

The greater the initial dose of capsaicin and the more frequent the applications, the sooner the desensitization will appear and pruritus disappear. Severe initial burning may be a side-effect of topical application. Cooling of the skin can also reduce the capsaicin-evoked burning. More unusual adverse effects of capsaicin include cough or sneezing due to inhalation of capsaicin from the skin or from the jar and its effect on sensory nerve fibres in the mucous membranes (91). It appears that such adverse effects are less bothersome for patients with severe pruritus compared to patients with slight pruritus (unpublished observations). A lower concentration of capsaicin and less frequent applications will induce tachyphylaxis later but may give a better compliance. The concentration of capsaicin varies in different studies, but 0.025% capsaicin is tolerated well by most patients. If capsaicin is not available in this concentration as a standard drug it can be produced using a lipophilic vehicle. Capsaicin is also well soluble in alcohol; capsaicin 0.025% in *spir dil* can be used to treat itchy scalp (not published). A weaker concentration of 0.006% capsaicin is recommended for intertriginous skin e.g. pruritus ani (93).

Topical capsaicin's effects have been confirmed in controlled clinical trials for different pain syndromes and neuropathy as well as notalgia paraesthetica (94), brachioradial pruritus (95), pruritic psoriasis (96, 97) and haemodialysis-related pruritus (98, 99). Case reports and case series described effects in hydroxyethyl starch-induced pruritus (100, 101), prurigo nodularis (100, 102–104), lichen simplex (100, 103), nummular eczema (100), aquagenic pruritus (105) and PUVA-associated pruritus (106).

Expert recommendation: Capsaicin can be effective in localised forms of CP, but patient compliance due to side-effects can restrict usage.

6.3.4. Cannabinoid receptor agonists. Topical cannabinoid receptor agonists are a new development since 2003 and appear to have antipruritic and analgesic properties. Experimentally induced pain, pruritus and erythema could be reduced by application of a topical cannabinoid agonist (107, 108). One cosmetic product containing the cannabinoid receptor and peroxisome proliferator-activated receptor alpha (PPAR- α) agonist, N-palmitoylethanolamine, is currently on the market. In (non-vehicle controlled) clinical trials and case series, it proved to have antipruritic effects in prurigo, AD, CKD-associated pruritus and PUO (109–111) as well as analgesic effects in postzoster neuralgia (112).

Expert recommendation: Cannabinoid receptor agonists can be effective in the treatment of localised pruritus.

6.3.5. Tacrolimus and pimecrolimus. The effects of tacrolimus and pimecrolimus on pruritus are mediated both through their immunological and neuronal properties (113). Paradoxically, while they can induce transient pruritus at the beginning of treatment, in the medium-term they may provide an alternative treatment for many causes of pruritus. They are very effective against pruritus in AD (114). Furthermore, tacrolimus ointment is more effective at reducing pruritus when compared with vehicle and pimecrolimus cream (114). Clinical trials have shown benefit of both pimecrolimus and tacrolimus in seborrhoeic dermatitis, genital lichen sclerosus, intertriginous psoriasis and cutaneous lupus erythematosus and – only for tacrolimus – in resistant idiopathic pruritus ani (115–122). In other diseases, the available data are limited to small case series, or individual cases e.g. hand eczema (pimecrolimus), rosacea (tacrolimus), graft-versus-host disease (tacrolimus), vulval pruritus (tacrolimus) or Netherton's syndrome (tacrolimus, pimecrolimus). Topical tacrolimus has been shown anecdotally to be effective in pruritus associated with systemic diseases such as PBC (123) and chronic renal insufficiency (124, 125). However, these observations have not been confirmed in a controlled study on CKD-associated pruritus (126, 127). Both substances can be used to treat localised forms of CP such as genital pruritus (128).

Expert recommendation: Tacrolimus and pimecrolimus are effective in localised forms of CP.

6.3.6. Acetylsalicylic acid. Topical acetylsalicylic acid (acetylsalicylic acid/dichlormethane solution) has been described to have antipruritic effects in occasional patients with lichen simplex (129). However, this beneficial effect could not be confirmed in experimentally induced itch with histamine (130).

Expert recommendation: Due to the lack of studies, topical acetylsalicylic acid can currently not be recommended for CP.

6.3.7. Doxepin. The tricyclic antidepressant doxepin showed antipruritic effects when applied as a 5% cream

in double-blind studies for treatment of AD (131), lichen simplex, nummular dermatitis and contact dermatitis (132). Topical doxepin therapy is not licensed and not used in any European country except for the UK (Xepin©) (133–135).

Expert recommendation: Due to the increased risk of contact allergy, especially when the treatment exceeds 8 days, topical doxepin cannot be recommended.

6.3.8. Zinc, menthol and camphor. Although zinc oxide has been used in dermatology for over 100 years due to its anti-inflammatory, antiseptic and anti-pruritic properties and its safety, there is only scarce literature on its effects. Prescriptions of zinc are frequent, with concentrations varying from 10 to 50% in creams, liniments, lotions, ointments and pastes that are useful in the treatment of pruritus, especially for localised forms of pruritus, in children as well as in adults (136).

Menthol is an alcohol obtained from mint oils, or prepared synthetically. Applied to the skin and mucous membranes, menthol dilates blood vessels, causing a sensation of coldness, followed by an analgesic effect (136). Menthol is used in dusting powders, liniments, lotions and ointments in concentrations from 1–10% (136). Menthol binds to the TRPM8 receptor (137) that belongs to the same TRP family of excitatory ion channels as TRPV1, the capsaicin receptor. These two receptors have been shown to co-exist occasionally in the same primary afferent neurons and promote thermosensations at a wide range of temperatures: 8–28°C and >50°C, respectively (137). Short-term application of such medications in CP in combination with other topical or systemic therapies can be recommended.

Camphor is an essential oil containing terpenes, it is soluble in alcohol (136). Applied to the skin it causes a sensation of warmth that is followed by a mild degree of anaesthesia (136). Camphor has been used in dermatology for decades in liniments, lotions and ointments in concentrations from 2–20%. It has been shown to specifically activate another constituent of the TRP ion channel family, namely TRPV3 (138). Recently, camphor was demonstrated to activate capsaicin receptor, TRPV1, while menthol also activates the camphor receptor, TRPV3. These findings illustrate the complexity of sensory perception and explain the efficacy of ointments containing both menthol and camphor (136).

Expert recommendation: Short term application of camphor, menthol and zinc in CP in combination with other topical or systemic therapies can be recommended.

6.3.9. Mast cell inhibitors. In a multi-center, double-blind, placebo-controlled trial, application of a 3% hydrogel formulation of tiacrilast against vehicle in AD led to no significant improvement of pruritus (139). Pruritus in AD responds to topical sodium cromoglycate (140), that was proved by a recent placebo-controlled study (141).

Expert recommendation: There is limited evidence to recommend the use of topical mast cell inhibitors for CP.

6.4. Systemic therapy

6.4.1. Antihistamines. Antihistamines are the most widely used systemic antipruritic drugs in dermatology. Most antihistamines that have been tried in pruritus belong to the H1 type. First generation antihistamines, such as chlorpheniramine, clemastine, cyproheptadine, diphenhydramine, hydroxyzine, and promethazine are known to bind not only to H1-receptors but also to muscarinic, α -adrenergic, dopamine or serotonin receptors and have a central sedative effect. Due to side effects, the application of sedative antihistamines is nowadays limited. Second generation antihistamines like cetirizine, levocetirizine, loratadine, desloratadine, ebastine, fexofenadine and rupafine have minimal activity on non-histaminic receptors, little sedative effect, and a longer duration of action compared to the first generation (142). Non-sedative H1-receptor antagonists offer an effective reduction of pruritus in diseases associated with increased mast cell degranulation like urticaria or mastocytosis (142). However, the doses required to alleviating pruritus in urticaria often amount to up to four times the licensed dose (143). Higher doses of the second generation antihistamines enhance their soporific side effects (142), which may contribute to their efficacy. A recent case series suggest that up dosing of antihistamines may also be beneficial in CP (144).

Systemic H1-antihistamines are often employed to combat itch in AD, but only sedative antihistamines have shown some benefit, mainly by improving sleep (145). Hydroxyzine is the most commonly used antihistaminic of the first generation showing sedative, anxiolytic and antipruritic activities. In adult patients it is recommended as an antipruritic agent in the dosage 75–100 mg/day. In children the effective dose is 1–2.5 mg/kg/day. In a controlled study, addition of hydroxyzine resulted in a 750-fold increase in the dose of histamine required to elicit itch. There was a five-fold increase following both cyproheptadine and placebo and a ten-fold increase following diphenhydramine (146). In addition, hydroxyzine was significantly more effective in reducing histamine-induced pruritus than neuroleptics, like thiothixene, chlorpromazine and thioridazine (147).

In addition, antihistamines are widely used as first-line drugs for treatment of CP associated with different systemic diseases such as chronic renal failure, cholestasis, hematopoietic diseases and thyroid disorders. However, conventional doses of antihistamines in the treatment of pruritus in internal diseases have not proven to be effective (142).

Although identified in human skin, H2-receptors play a minor role in pruritus and H2-receptor antagonists alone have no antipruritic effect (145, 148). A com-

bination of H2-antihistamines and H1-antihistamines has been used in treatment of pruritus in small trials but the results are conflicting (145, 148). A combination of H1-antihistamine with a leukotriene antagonist has been reported to alleviate pruritus in chronic urticaria (149).

Expert recommendation: Antihistamines are effective in treating CP in urticaria. Antihistamines are of some value for itch in AD and CP of diverse origin. As there is limited evidence of antipruritic effects of non-sedating antihistamines in AD, PV and CP of diverse origin, sedating antihistamines can be recommended to be applied during night time for sleep improvement. Hydroxyzine is the first choice of the majority of physicians trying to control CP but its sedative effect may contraindicate its use in the elderly.

6.4.2. Mast cell inhibitors. Ketotifen, a mast cell stabilizer, showed antipruritic effects in single patients with CKD-associated pruritus (150). Two patients with CKD-associated pruritus (151) and Hodgkin's lymphoma (152) showed a significant antipruritic effect with the mast cell stabilizer cromoglicic acid.

Expert recommendation: There is insufficient evidence to recommend the systemic use of mast cell inhibitors for CP.

6.4.3. Glucocorticosteroids. There are no studies investigating the efficacy of the exclusive use of systemic glucocorticosteroids in CP. In clinical experience, pruritus ceases within approximately 30 min of i.v. glucocorticosteroids in the treatment of urticaria or drug-induced exanthema. Likewise, in AD, allergic contact dermatitis, dyshidrosis and bullous pemphigoid, rapid reduction of pruritus is observed, which can be explained by the high anti-inflammatory potency of glucocorticosteroids. Thus, while systemic glucocorticosteroids should not be considered as an antipruritic drug for long-term therapy, short-term use is possible in cases of severe pruritus, but should not be prescribed for a period of more than two weeks (153) because of severe side-effects.

Prednisone is the most commonly selected oral corticosteroid initially at a daily dose that can range from 2.5–100 mg daily or more, usually starting in a dose of 30–40 mg daily. In exceptional cases, i.v. methylprednisolone is used at a dose of 500 mg/day to 1 g/day, because of its high potency and low sodium-retaining activity. It is important to remember that the dosage should be tapered in accordance with the severity of pruritus. Before discontinuing systemic therapy one may change to topical corticosteroid therapy. Corticosteroids should be used with caution in children and the elderly as well as in patients with relevant metabolic disorders such as diabetes.

Expert recommendation: Systemic corticosteroids can be used as short-term treatment in severe cases of CP, but should not be used for longer than 2 weeks.

6.4.4. Opioid receptor agonists and antagonists. Experimental and clinical observations have demonstrated that pruritus can be evoked or intensified by endogenous or exogenous μ -opioids (154). This phenomenon can be explained by activation of spinal opioid receptors, mainly κ -opioid receptors. Reversing this effect with μ -opioid antagonists thus leads to an inhibition of pruritus (112). The opposite is true for κ -opioids. Their binding to κ -opioid receptors leads to inhibition of pruritus (155).

Several clinical studies have demonstrated that different μ -opioid receptor antagonists may significantly diminish pruritus (30, 33, 156–160). In double-blind RCT, μ -opioid receptor antagonists such as nalmefine, naloxone and naltrexone have exhibited high antipruritic potency. For example, pruritus in chronic urticaria, AD, and cholestatic pruritus has shown therapeutic response to nalmefene (10 mg twice daily) and naltrexone (50–100 mg/day) (161, 162). Controlled studies have also been performed in patients with CKD-associated pruritus (26, 27, 163). Results were variable from significant reduction of pruritus to no response. Case reports have demonstrated efficacy in prurigo nodularis, macular amyloidosis, lichen amyloidosis, pruritus in mycosis fungoides, psoriasis vulgaris, aquagenic pruritus, hydroxyethyl starch-induced pruritus and PUO.

Nalfurafine, a preferential κ -opioid receptor agonist, was investigated in CKD-associated CP in two large RTCs (25, 164). Both trials demonstrated significant clinical benefit of nalfurafine in patients with uremic pruritus (155) within the first seven days of treatment. The drug is currently licensed in Japan only.

Expert recommendation: Opioid receptor antagonists may be effective in cholestatic pruritus and AD but their side-effect profile needs to be considered. Nalfurafine can be applied in Japanese patients with uremic pruritus.

6.4.5. Gabapentin and pregabalin. Gabapentin is an antiepileptic drug, also used in neuropathic disorders causing pain or pruritus (165). The mechanisms of action of gabapentin, a 1-amino-methyl-cyclo-hexane acetic acid and a structural analogue of the inhibitory neurotransmitter γ -aminobutyric acid (GABA) remain unclear. It is used in postherpetic neuralgia (166), especially with paroxysmal pain or pruritus. Anecdotal indications are brachioradial pruritus (167) and cutaneous T-cell lymphoma (168). Pilot studies have been performed for the treatment of pruritus caused by burns and wound healing in children demonstrating antipruritic effects of gabapentin (169). Double-blind, randomised, placebo-controlled trials were performed for CKD-associated pruritus (170) and cholestatic pruritus (171). Gabapentin was safe and effective for treating CKD-associated pruritus (172, 173). Pregabalin is similar to gabapentin and a more recent drug. Its use has been suggested in a case of cetuximab-related pruritus and aquagenic pruritus (174, 175). A recent

controlled trial demonstrated a significant antipruritic effect of pregabalin in patients on haemodialysis within one month (176).

Expert recommendation: Gabapentin and pregabalin can be recommended in the treatment of CKD-associated pruritus and neuropathic CP.

6.4.6. Antidepressants. Psychoemotional factors are known to modulate the 'itch threshold.' Under certain circumstances, they can trigger or enhance CP (177). Itch is a strong stressor and can elicit psychiatric disease and psychological distress. Depressive disorders are present in about 10% of patients with CP (77). Consequently, depressive symptoms are treated in these patients, and some antidepressants also exert an effect on pruritus through their pharmacological action on serotonin and histamine. SSRIs, such as paroxetine, can have an antipruritic effect on patients with PV, psychogenic or paraneoplastic pruritus and other patients with chronic PUO (178). Antidepressants, like mirtazapine (179) and especially doxepin (180) have been effective in urticaria, AD and HIV-related pruritus.

The SSRI paroxetine (20 mg/day) has exhibited antipruritic effects in pruritus due to PV (181), paraneoplastic pruritus (182, 183) and psychiatric disease (184). In two patients, pruritus was induced by discontinuation of paroxetine treatment for depression (185). A RCT in pruritus of non-dermatologic origin confirmed the antipruritic effect of paroxetine (178). In a two-armed proof-of-concept study with paroxetine and fluvoxamine, patients with CP of dermatological origin reported significant antipruritic effect (186). Sertraline proved efficacy in cholestatic pruritus as demonstrated in a RCT (187). As severe cardiac side effects have been described, especially in elderly, this therapy should be used with caution. A psychosomatic/psychiatric examination before starting the treatment is recommended because of its stimulative effects.

Expert recommendation: SSRIs can be recommended for the treatment of somatoform pruritus, paraneoplastic CP, PUO and cholestatic pruritus. Mirtazapine can be recommended in CP of AD.

6.4.7. Serotonin receptor antagonists. Due to the pathophysiological significance of serotonin in different diseases such as kidney and liver diseases, serotonin receptor antagonists (of the 5-HT₃ type) such as ondansetron (8 mg 1–3/day), topisetron (5 mg/day) and granisetron (1 mg/day) have been used anecdotally to treat pruritus (188–194). Contradictory or negative results have been reported in partly controlled studies using ondansetron for cholestatic pruritus (188, 195, 196) and opioid-induced pruritus (197–199). An antipruritic effect was reported for ondansetron in CKD-associated pruritus (200). However, this could not be confirmed in subsequent controlled studies (201–203) later on.

Expert recommendation: Due to the lack of convincing evidence, serotonin receptor antagonists cannot be recommended in the treatment of CP.

6.4.8. Thalidomide. A number of mechanisms for the antipruritic action of thalidomide have been proposed including a central depressant effect (204), a local effect on proliferated neural tissue in PN (205), and the antagonism of TNF- α (206).

The best results with thalidomide in CP have been achieved in PN. Several studies have shown a rapid decrease of pruritus on thalidomide (50–300 mg/day) (207, 208). A prospective open trial of thalidomide 100 mg/day, followed by narrow-band UVB (TL-01) showed a high response with minimal side-effects (209). Likewise, good results have been seen in HIV-positive patients with PN (210). There is one randomised double-blind cross-over trial of the successful treatment of CKD-associated pruritus with thalidomide (211). Thalidomide is teratogenic and there is a dose-related risk of neuropathy, especially in high daily doses (>100 mg/day) (212).

Expert recommendation: Though there is evidence for its antipruritic effect, thalidomide is not recommended for the treatment of CP due to its side effects.

6.4.9. Leukotriene receptor antagonist, TNF antagonists. Leukotriene receptor antagonists (e. g. montelukast) and TNF- α antagonists influence the pathogenesis of AD. They have been used in combination with antihistamines as antipruritic therapy. Montelukast has also been used in several types of urticaria as well as in combination with antihistamines. A combination of H1-antihistamine with a leukotriene antagonist has been reported to alleviate pruritus in chronic urticaria (204).

Expert recommendation: Due to the lack of evidence, leukotriene receptor antagonists and TNF antagonists cannot be recommended in the treatment of CP.

6.4.10. Cyclosporin A. Pruritus in AD responds to treatment with cyclosporin A as demonstrated in controlled double-blind studies (213, 214). Cyclosporin A has been administered in PN for 24 to 36 weeks, using doses of 3.0–4.5 mg/kg/day. Improvement was observed in both pruritus and skin lesions after two weeks of treatment (215, 216). It seems likely that in these diseases cyclosporin A acts on pruritus through its immunological effects. However, direct effects on nerve endings are also possible, suggested by successful use in non-immunological diseases as reported in several studies, e. g. 10 patients with senescent pruritus were treated with cyclosporin A 5 mg/kg/day for 8 weeks (217). All patients of this uncontrolled, open study responded. Case reports describe antipruritic effects in dystrophic epidermolysis bullosa associated CP and in CKD-associated pruritus (218, 219).

Expert recommendation: Cyclosporin A can be recommended in the treatment of CP in AD or in PN.

6.4.11. Aprepitant. Substance P (SP) has a dominant role in pruritus induction in the skin. Via binding to the neurokinin 1 receptor (NK1) on keratinocytes, blood vessels and mast cells, SP promotes inflammation and mast cell degranulation. SP is released from sensory neurons. In conditions with hyperplasia of skin nerves (AD, PN), SP levels are increased. Accordingly, inhibition of the pruritogenic effects of SP by blocking the corresponding receptor may have antipruritic effects. Several case reports suggest a positive role of the NK1 receptor antagonist aprepitant in CP, e.g. cutaneous T-cell lymphoma, solid tumours and drug-induced pruritus (220–223). Recently, a proof-of-concept study in 20 patients showed significant, antipruritic effects in chronic, therapy-refractory pruritus of various origins with a one-week monotherapy of aprepitant (224). The highest response rate was observed in patients with atopic diathesis and PN. RCT are missing.

Expert recommendation: NK1 antagonists, in particular aprepitant, are promising substances in the therapy of CP. Aprepitant might be used as a second-line option in therapy refractory cases, e.g. in patients with AD and PN.

6.5. UV phototherapy

Ultraviolet (UV)-based therapy is well established for treating pruritus and utilizes UVB (290–320 nm) and UVA (320–400 nm). The light sources include broadband UVB (BB-UVB, 290–320 nm, peaks at 313 nm), narrowband UVB (NB-UVB, 311 nm), broadband UVA (320–400 nm, peaks at 355 nm), and UVA1 (340–400 nm, peaks at 365 nm) (225).

Inflammatory dermatoses associated with pruritus respond well to different UV treatments including UVB 311. For the treatment of AD, early studies demonstrated that UVB was better than placebo (226). In a recent study NB-UVB was better than BB-UVA and both were better than placebo (227). In the treatment of pruritus of AD, BB-UVB and UVA were equally effective in a half-body comparison (228). In a more recent study, NB-UVB was insignificantly better than UVA1 for pruritus (229). In AD, phototherapy seems to act locally rather than systemically: When one half of the body was treated with UVB and the other half was not, only the treated side improved (226).

For the treatment of prurigo PUVA, UVA1 and NB-UVB proved to be effective in a RCT, with PUVA and UVA1 superior to NB-UVB (230).

For many other skin diseases, a number of studies have demonstrated the efficacy of UV treatment, e.g. psoriasis, lichen planus, T-cell lymphoma, solar, chronic, and idiopathic urticaria, and urticaria pigmentosa.

It can be assumed that in cases of pruritic inflammatory dermatoses pruritus is reduced by inhibiting pro-inflammatory mediators and induction of anti-

inflammatory and immunosuppressive factors. UVB mainly affects epidermal keratinocytes and Langerhans' cells, due to its limited penetration into the skin. UVA1, in contrast, reaches to the dermis and therefore can affect T lymphocytes, mast cells, and dermal dendritic cells, e.g. induces apoptosis of these cells (225). However, UVB-induced apoptosis of mast cells has been argued to explain relief of pruritus (231). Furthermore, phototherapy leads to a reduction of CGRP-immunoreactive nerve fibres in the skin (232).

In conditions with pruritus on primarily non-inflamed skin, UV therapy has been particularly effective in CKD-associated pruritus (233, 234). In a placebo-controlled trial, UVA alone was ineffective for this condition (235). However, an antipruritic effect was seen in CKD-associated pruritus when treated with combined UVA/UVB phototherapy (236). BB-UVB alone was effective in treating CKD-associated pruritus. It was remarkable that in spite of placebo control (only one body half was treated) an improvement of pruritus occurred over the entire body (237), suggesting a systemic antipruritic effect. In an open pilot study using NB-UVB 14/20, CKD-associated pruritus patients responded well to treatment (238). Also in a recent study NB-UVB appeared to be effective in reduction of CKD-associated pruritus (239). However in another case NB-UVB treatment was unsuccessful, but BB-UVB helped (240).

UV therapy has also been reported to be effective in a number of cases of metabolic itch. In PV, 8/10 patients responded to NB-UVB in an open study (241). Aquagenic pruritus has shown response to bath PUVA therapy (242) and systemic PUVA (243) for the duration of therapy. To treat aquagenic pruritus, PUVA was found to be superior to BB-UVB in 5 patients (244). Recently, two patients with aquagenic pruritus have been reported with a good, but ephemeral response to NB-UVB (245).

In HIV patients with pruritus, UVB produced significant relief of pruritus in an open study with 21 patients (33% primary pruritus, 66% eosinophilic folliculitis) (246). In a single case report, a patient with Hodgkin's disease responded well to BB-UVB (247).

A retrospective analysis of children up to the age of 18 years suffering from AD and psoriasis suggests NB-UVB treatment (248). In children, longer follow-up is essential to determine true carcinogenic risk of UV therapy.

Expert recommendation: UV therapy can be applied for CP. The mode of UV phototherapy depends on the underlying disease. UVA as well as UVB (NB-UVB/BB-UVB) as well as a combination of UVA/UVB relieve CP in certain diseases. UV phototherapy can be used in combination with topical and/or systemic treatment except for calcineurin inhibitors and immunosuppressant drugs.

6.6. Psychosomatic therapy (relaxation techniques and psychotherapy)

The vicious itch-scratch cycle has to be taken into account when a patient is treated for pruritus. In addition to causal and symptomatic therapy, behavioural therapy to avoid scratching should be considered, e.g. conscious suppression of the reflex by intense concentration, distraction or alternative scratching techniques such as habit reversal (249). This is very important in patients with prurigo nodularis who might show an unconscious automatic scratching behaviour.

Adjuvant psychosocial programmes are most effective in AD (72, 250–252). Such programmes include strategies for breaking the vicious circle of itching and scratching, relaxation and stress management techniques as well as strategies for dealing with relapses. A similar educational programme was developed for patients with CP (253, 254). It is currently established for in-patient hospital treatment of patients with pruritic dermatoses using behavioural therapy in the context of an integrated psychosomatic treatment (255, 256). In patients with coexisting depression, psychotherapy in combination with psychotropic medication can be helpful even to treat pruritus of different aetiology (257). Most publications on psychotherapeutic/psychopharmacologic interventions, however, refer to small groups or single case reports. In neurotic excoriations, combined psychopharmacotherapy is also often indicated (257–260).

Expert recommendation: Relaxation techniques and education programmes for CP patients are useful as a complementary treatment for managing CP.

7. KEY SUMMARY OF DISCUSSION CONCERNING COUNTRY-SPECIFIC PROCEDURES

- Antihistamines: Sedative H1 antihistamines are first-choice therapy in CP to improve night-time sleep. Studies on application of higher doses are yet to be conducted.
- UV phototherapy is recommended for generalised pruritus, especially in elderly pruritus patients or in case of contraindications for systemic therapy.
- Anticonvulsants/pain modulators are recommended in neuropathic pruritus.
- Antidepressants are recommended in forms of CP not responding to other therapies.
- Systemic glucocorticosteroids are not recommended for treatment of CP except of very severe and desperate cases.
- Serotonin receptor antagonists and thalidomide are not recommended for treatment.

This guideline is in accordance with the EDF guideline on chronic pruritus finished in 2010 (www.euroderm.org). This is an updated version.

ACKNOWLEDGEMENT

We thank Erika Schulz and Dr. Reginald Scheidt very much for their great help and assistance in the preparation of this manuscript.

8. REFERENCES

- Weisshaar EW, Dalgard F. Epidemiology of itch: adding to the burden of skin morbidity. *Acta Derm Venereol* 2009; 89: 339–350.
- Ständer S, Weisshaar E, Mettang T, Szepietowski JC, Carstens E, Ikoma A, et al. Clinical classification of itch: a position paper of the International Forum for the Study of Itch. *Acta Derm Venereol* 2007; 87: 291–294.
- Ständer S, Weisshaar E, Mettang T, Streit M, Darsow U, Schneider G, et al. Klinische Klassifikation von chronischem Pruritus. Interdisziplinärer Konsensusvorschlag für einen diagnostischen Algorithmus. *Hautarzt* 2006; 57: 390–394.
- Darsow U, Wollenberg A, Simon D, Taieb A, Werfel T, Oranje A, et al. ETFAD/EADV eczema task force 2009 position paper on diagnosis and treatment of atopic dermatitis. *J Eur Acad Dermatol Venereol* 2010; 24: 317–328.
- Misery L, Alexandre S, Dutray S, Chastaing M, Consoli SG, Audra H, et al. Functional itch disorder or psychogenic pruritus: suggested diagnosis criteria from the French psychodermatology group. *Acta Derm Venereol* 2007; 87: 341–344.
- Magerl M, Borzova E, Giménez-Arnau A, Grattan CEH, Lawlor F, Mathelier-Fusade P, et al. The definition and diagnostic testing of physical and cholinergic urticarias 2009; EAAC/GA_LEN/EDF/UNEV consensus panel recommendations. *Allergy* 2009; 64: 1715–1721.
- Rea JN, Newhouse ML, Halil T. Skin disease in Lambeth. A community study of prevalence and use of medical care. *Br J Prev Soc Med* 1976; 30: 107–114.
- Zylicz Z, Twycross R, Jones EA. Pruritus in advanced disease. Oxford: Oxford University Press; 2004.
- Dalgard F, Svensson A, Holm JO, Sundby J. Self-reported skin morbidity in Oslo. Associations with sociodemographic factors among adults in a cross-sectional study. *Br J Dermatol* 2004; 151: 452–457.
- Dalgard F, Dawn AG, Yosipovitch G. Are itch and chronic pain associated in adults? Results of a large population survey in Norway. *Dermatology* 2007; 214: 305–309.
- Matterne U, Apfelbacher C, Loerbroks A. Prevalence, correlates and characteristics of chronic pruritus: a population-based cross-sectional study. *Acta Derm Venereol* 2011; 91: 674–679.
- Ständer S, Schäfer I, Phan NQ, Blome C, Herberger K, Heigel H, et al. Prevalence of chronic pruritus in Germany: results of a cross-sectional study in a sample working population of 11,730. *Dermatology* 2010; 221: 229–235.
- Yosipovitch G, Goon AT, Wee J, Chan YH, Zucker I, Goh CL. Itch characteristics in Chinese patients with atopic dermatitis using a new questionnaire for the assessment of pruritus. *Int J Dermatol* 2002; 41: 212–216.
- Szepietowski JC, Reich A, Wisnicka B. Itching in patients suffering from psoriasis. *Acta Dermatovenereol Croat* 2002; 10: 221–226.
- Szepietowski JC, Reich A, Wisnicka B. Pruritus and psoriasis. *Br J Dermatol* 2004; 151: 1284.
- Szepietowski JC, Salomon J. Uremic pruritus: still an important clinical problem. *J Am Acad Dermatol* 2004; 51: 842–843.
- Britt H, Pan Y, Miller GC, Valenti L, Charles J, Knox S, et al. Presentations of ‘itch’ in Australian general practice. *Aust Fam Physician* 2004; 33: 488.
- McCormick A, Fleming D, Charlton J. Morbidity Statistics from General Practice. Fourth national study 1991–1992. London: Her Majesty’s Stationery Office; 1995.
- Symvoulakis EK, Krasagakis K, Komninos ID, Kastrinakis I, Lyronis I, Philalithis A, et al. Primary care and pattern of skin diseases in a Mediterranean island. *BMC Fam Pract* 2006; 7: 6.
- Kimmel M, Alschler DM, Dunst R, Braun N, Machleidt C, Kiefer T, et al. The role of micro-inflammation in the pathogenesis of uraemic pruritus in haemodialysis patients. *Nephrol Dial Transplant* 2006; 21: 749–755.
- Blachley JD, Blankenship DM, Menter A, Parker TF, 3rd, Knochel JP. Uremic pruritus: skin divalent ion content and response to ultraviolet phototherapy. *Am J Kidney Dis* 1985; 5: 237–241.
- Stähle-Bäckdahl M, Hagermark O, Lins LE, Torring O, Hilliges M, Johansson O. Experimental and immunohistochemical studies on the possible role of parathyroid hormone in uraemic pruritus. *J Intern Med* 1989; 225: 411–415.
- Stockenhuber F, Sunder-Plassmann G, Balcke P. Increased plasma histamine levels in chronic renal failure. *N Engl J Med* 1987; 317: 386.
- Dugas-Breit S, Schopf P, Dugas M, Schiffl H, Rueff F, Przybilla B. Baseline serum levels of mast cell tryptase are raised in hemodialysis patients and associated with severity of pruritus. *J Dtsch Dermatol Ges* 2005; 3: 343–347.
- Wikstrom B, Gellert R, Ladefoged SD, Danda Y, Akai M, Ide K, et al. Kappa-opioid system in uraemic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies. *J Am Soc Nephrol* 2005; 16: 3742–3747.
- Peer G, Kivity S, Agami O, Fireman E, Silverberg D, Blum M, et al. Randomised crossover trial of naltrexone in uraemic pruritus. *Lancet* 1996; 348: 1552–1554.
- Pauli-Magnus C, Mikus G, Alschler DM, Kirschner T, Nagel W, Gugeler N, et al. Naltrexone does not relieve uraemic pruritus: results of a randomized, double-blind, placebo-controlled crossover study. *J Am Soc Nephrol* 2000; 11: 514–519.
- Duque MI, Thevarajah S, Chan YH, Tuttle AB, Freedman BI, Yosipovitch G. Uremic pruritus is associated with higher kt/V and serum calcium concentration. *Clin Nephrol* 2006; 66: 184–191.
- Mettang T, Pauli-Magnus C, Alschler DM. Uraemic pruritus - new perspectives and insights from recent trials. *Nephrol Dial Transplant* 2002; 17: 1558–1563.
- Bergasa NV. The pruritus of cholestasis. *J Hepatol* 2005; 43: 1078–1088.
- Bergasa NV, Mehlman JK, Jones EA. Pruritus and fatigue in primary biliary cirrhosis. *Baillieres Best Pract Res Clin Gastroenterol* 2000; 14: 643–655.
- Cacoub P, Poynard T, Ghillani P, Charlotte F, Olivi M, Piette JC, et al. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. *Arthritis Rheum* 1999; 42: 2204–2212.
- Bergasa NV, Schmitt JM, Talbot TL, Alling DW, Swain MG, Turner ML, et al. Open-label trial of oral nalmefene therapy for the pruritus of cholestasis. *Hepatology* 1998; 27: 679–684.
- Kremer AE, Dijk RV, Leckie P, Schaap FG, Kuiper EM, Mettang T, et al. Serum autotaxin is increased in pruritus of cholestasis, but not of other origin and responds to therapeutic interventions. *Hepatology* 2012 (Epub ahead of print).
- Neilly JB, Martin A, Simpson N, MacCuish AC. Pruritus

- in diabetes mellitus: investigation of prevalence and correlation with diabetes control. *Diabetes Care* 1986; 9: 273–275.
36. Jabbour SA. Cutaneous manifestations of endocrine disorders: a guide for dermatologists. *Am J Clin Dermatol* 2003; 4: 315–331.
 37. Caravati CM, Jr., Richardson DR, Wood BT, Cawley EP. Cutaneous manifestations of hyperthyroidism. *South Med J* 1969; 62: 1127–1130.
 38. Adams S. Iron deficiency, serum ferritin, generalized pruritus and systemic disease: a case control study. *Br J Dermatol* 1989; 121: 15.
 39. Nestler JE. Hemochromatosis and pruritus. *Ann Intern Med* 1983; 98: 1026.
 40. Hamilton DV, Gould DJ. Generalized pruritus as a presentation of idiopathic haemochromatosis. *Br J Dermatol* 1985; 112: 629.
 41. Bernhard JD. *Itch: Mechanisms and management of pruritus*. New York: McGraw-Hill; 1994.
 42. Diehn F, Tefferi A. Pruritus in polycythaemia vera: prevalence, laboratory correlates and management. *Br J Haematol* 2001; 115: 619–621.
 43. Egli F, Wieczorek A, Niemoller M, Rhyner K. Polycythaemia vera: klinik und verlauf bei 86 patienten. *Schweiz Med Wochenschr* 1988; 118: 1969–1975.
 44. Gilbert HS, Warner RR, Wasserman LR. A study of histamine in myeloproliferative disease. *Blood* 1966; 28: 795–806.
 45. Pieri L, Bogani C, Guglielmelli P, Zingariello M, Rana RA, Bartalucci N, et al. The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera. *Haematologica* 2009; 94: 1537–1545.
 46. Krajnik M, Zyllicz Z. Pruritus in advanced internal diseases. Pathogenesis and treatment. *Neth J Med* 2001; 58: 27–40.
 47. Brunner W. Pruritus – auch eine internistische Herausforderung. *Schweiz Med Wochenschr* 1995; 125: 2244–2250.
 48. Gelfand JM, Rudikoff D. Evaluation and treatment of itching in HIV-infected patients. *Mt Sinai J Med* 2001; 68: 298–308.
 49. Eisman S. Pruritic papular eruption in HIV. *Dermatol Clin* 2006; 24: 449–457.
 50. Afifi Y, Aubin F, Puzenat E, Degouy A, Aubrion D, Hassam B, et al. Enquete etiologique d'un prurit sine materia: etude prospective d'une serie de 95 patients. *Rev Med Interne* 2004; 25: 490–493.
 51. Canavero S, Bonicalzi V, Massa-Micon B. Central neurogenic pruritus: a literature review. *Acta Neurol Belg* 1997; 97: 244–247.
 52. Adreiev VC, Petkov I. Skin manifestations associated with tumours of the brain. *Br J Dermatol* 1975; 92: 675–678.
 53. Savk E, Savk O, Bolukbasi O, Culhaci N, Dikicioglu E, Karaman G, et al. Notalgia paresthetica: a study on pathogenesis. *Int J Dermatol* 2000; 39: 754–759.
 54. Savk O, Savk E. Investigation of spinal pathology in notalgia paresthetica. *J Am Acad Dermatol* 2005; 52: 1085–1087.
 55. Goodkin R, Wingard E, Bernhard JD. Brachioradial pruritus: cervical spine disease and neurogenic/neuropathic (corrected) pruritus. *J Am Acad Dermatol* 2003; 48: 521–524.
 56. Marziniak M, Phan NQ, Raap U, Siepmann D, Schurmeyer-Horst F, Pogatzki-Zahn E, et al. Brachioradial pruritus as a result of cervical spine pathology: the results of a magnetic resonance tomography study. *J Am Acad Dermatol* 2011; 65: 756–762.
 57. Reich A, Ständer S. Drug-induced Pruritus: A Review. *Acta Derm Venereol* 2009; 89: 236–244.
 58. Kaplan AP. Drug-induced skin disease. *J Allergy Clin Immunol* 1984; 74: 573–579.
 59. Metzke D, Reimann S, Szepefalusi Z, Bohle B, Kraft D, Luger TA. Persistent pruritus after hydroxyethyl starch infusion therapy: a result of long-term storage in cutaneous nerves. *Br J Dermatol* 1997; 136: 553–559.
 60. Beauregard S, Gilchrist BA. A survey of skin problems and skin care regimens in the elderly. *Arch Dermatol* 1987; 123: 1638–1643.
 61. Yalcin B, Tamer E, Toy GG, Oztas P, Hayran M, Alli N. The prevalence of skin diseases in the elderly: analysis of 4099 geriatric patients. *Int J Dermatol* 2006; 45: 672–676.
 62. Thaipisuttikul Y. Pruritic skin diseases in the elderly. *J Dermatol* 1998; 25: 153–157.
 63. Sommer F, Hensen P, Bockenholt B, Metzke D, Luger TA, Ständer S. Underlying diseases and co-factors in patients with severe chronic pruritus: a 3-year retrospective study. *Acta Derm Venereol* 2007; 87: 510–516.
 64. Weisshaar E, Diepgen TL, Luger TA, Seeliger S, Witteler R, Ständer S. Pruritus in pregnancy and childhood – do we really consider all relevant differential diagnoses? *Eur J Dermatol* 2005; 15: 320–331.
 65. Ambros-Rudolph CM, Mullegger RR, Vaughan-Jones SA, Kerl H, Black MM. The specific dermatoses of pregnancy revisited and reclassified: results of a retrospective two-center study on 505 pregnant patients. *J Am Acad Dermatol* 2006; 54: 395–404.
 66. Holmes RC. Polymorphic eruption in pregnancy. *Sem Dermatol* 1988; 8: 18–22.
 67. *Girling JC. Obstetric cholestasis. Guideline no 43*. London: Royal College of Obstetricians and Gynaecologists (RCOG); 2006.
 68. Reyes H, Gonzalez MC, Ribalta J, Aburto H, Matus C, Schramm G, et al. Prevalence of intrahepatic cholestasis of pregnancy in Chile. *Ann Intern Med* 1978; 88: 487–493.
 69. Reyes H, Taboada G, Ribalta J. Prevalence of intrahepatic cholestasis of pregnancy in La Paz, Bolivia. *J Chronic Dis* 1979; 32: 499–504.
 70. Clark TJ, Dwarakanath L, Weaver JB. Pruritus in pregnancy and obstetric cholestasis. *Hosp Med* 1999; 60: 254–260.
 71. Staab D, Diepgen TL, Fartasch M, Kupfer J, Lob-Corzilius T, Ring J, et al. Age related, structured educational programmes for the management of atopic dermatitis in children and adolescents: multicentre, randomised controlled trial. *BMJ* 2006; 332: 933–938.
 72. Weisshaar E, Diepgen TL, Bruckner T, Fartasch M, Kupfer J, Lob-Corzilius T, et al. Itch intensity evaluated in the German Atopic Dermatitis Intervention Study (GADIS): correlations with quality of life, coping behaviour and SCORAD severity in 823 children. *Acta Derm Venereol* 2008; 88: 234–239.
 73. Halvorsen JA, Dalgard F, Thoresen M, Thoresen M, Bjertness E, Lien L. Itch and mental distress: a cross-sectional study among late adolescents. *Acta Derm Venereol* 2009; 89: 39–44.
 74. Lim YL, Chan YH, Yosipovitch G, Greaves MW. Pruritus is a common and significant symptom of acne. *J Eur Acad Dermatol Venereol* 2008; 22: 1332–1336.
 75. Reich A, Trybucka K, Tracinska A, Samotij D, Jasiuk B, Srama M, et al. Acne itch: do acne patients suffer from itching? *Acta Derm Venereol* 2008; 88: 38–42.
 76. Weisshaar E, Apfelbacher C, Jager G, Zimmermann E, Bruckner T, Diepgen TL, et al. Pruritus as a leading

- symptom: clinical characteristics and quality of life in German and Ugandan patients. *Br J Dermatol* 2006; 155: 957–964.
77. Schneider G, Driesch G, Heuft G, Evers S, Luger TA, Ständer S. Psychosomatic cofactors and psychiatric comorbidity in patients with chronic itch. *Clin Exp Dermatol* 2006; 31: 762–767.
 78. Weisshaar E, Gieler U, Kupfer J, Furue M, Saeki H, Yosipovitch G. Questionnaires to Assess Chronic Itch: A Consensus Paper of the Special Interest Group (SIG) of the International Forum on the Study of Itch (IFSI). *Acta Derm Venereol* 2012; 92: 493–496.
 79. Phan NQ, Blome C, Fritz F, Gerss J, Reich A, Ebata T, et al. Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. *Acta Derm Venereol* 2012; 92: 502–507.
 80. Reich A, Heisig M, Phan NQ, Taneda K, Takamori K, Takeuchi S, et al. Visual Analogue Scale: Evaluation of the Instrument for the Assessment of Pruritus. *Acta Derm Venereol* 2012; 92: 497–501.
 81. Pfaf F, Valet M, Sprenger T, Huss-Marp J, Athanasiadis GI, Baurecht HJ, et al. Temperature modulated histamine-itch in lesional and nonlesional skin in atopic eczema – a combined psychophysical and neuroimaging study. *Allergy* 2010; 65: 84–94.
 82. Zuberbier T, Bindslev-Jensen C, Canonica W, Grattan CE, Greaves MW, Henz BM, et al. EAACI/GALEN guideline: management of urticaria. *Allergy* 2005; 61: 321–331.
 83. European Association for the Study of the Liver. Clinical Practice Guideline: Management of cholestatic liver disease. *J Hepatol* 2009; 51: 237–267.
 84. Weisshaar E, Forster C, Dotzer M, Heyer G. Experimentally induced pruritus and cutaneous reactions with topical antihistamine and local analgesics in atopic eczema. *Skin Pharmacol* 1997; 10: 183–190.
 85. Weisshaar E, Heyer G, Forster C, Hornstein OP, Handwerker HO. Antipruritic effect of antihistaminergic and lokalanesthetischer Externa nach iontophoretischem Histaminreiz. *Hautarzt* 1996; 47: 355–360.
 86. Layton AM, Cotterill JA. Notalgia paraesthetica – report of three cases and their treatment. *Clin Exp Dermatol* 1991; 16: 197–198.
 87. Zhai H, Frisch S, Pelosi A, Neibart S, Maibach HI. Antipruritic and thermal sensation effects of hydrocortisone creams in human skin. *Skin Pharmacol Appl Skin Physiol* 2000; 13: 352–357.
 88. Szczepanowska J, Reich A, Szepietowski JC. Emollients improve treatment results with topical corticosteroids in childhood atopic dermatitis: a randomized comparative study. *Pediatr Allergy Immunol* 2008; 19: 614–618.
 89. Al-Ghnam R, Short K, Pullen A, Fuller LC, Rennie JA, Leather AJ. 1% hydrocortisone ointment is an effective treatment of pruritus ani: a pilot randomized controlled crossover trial. *Int J Colorectal Dis* 2007; 22: 1463–1467.
 90. Kawashima M, Tango T, Noguchi T, Inagi M, Nakagawa H, Harada S. Addition of fexofenadine to a topical corticosteroid reduces the pruritus associated with atopic dermatitis in a 1-week randomized, multicentre, double-blind, placebo-controlled, parallel-group study. *Br J Dermatol* 2003; 148: 1212–1221.
 91. Szolcsanyi J. Forty years in capsaicin research for sensory pharmacology and physiology. *Neuropeptides* 2004; 38: 377–384.
 92. Wallengren J, Hakanson R. Effects of capsaicin, bradykinin and prostaglandin E2 in the human skin. *Br J Dermatol* 1992; 126: 111–117.
 93. Lysy J, Sistiery-Ittah M, Israelit Y, Shmueli A, Strauss-Liviatan N, Mindrul V, et al. Topical capsaicin – a novel and effective treatment for idiopathic intractable pruritus ani: a randomised, placebo controlled, crossover study. *Gut* 2003; 52: 1323–1326.
 94. Wallengren J, Klinker M. Successful treatment of notalgia paraesthetica with topical capsaicin: vehicle-controlled, double-blind, crossover study. *J Am Acad Dermatol* 1995; 32: 287–289.
 95. Wallengren J. Brachioradial pruritus: a recurrent solar dermopathy. *J Am Acad Dermatol* 1998; 39: 803–806.
 96. Ellis CN, Berberian B, Sulica VI, Dodd WA, Jarratt MT, Katz HI, et al. A double-blind evaluation of topical capsaicin in pruritic psoriasis. *J Am Acad Dermatol* 1993; 29: 438–442.
 97. Bernstein JE, Parish LC, Rapaport M, Rosenbaum MM, Roenigk HH, Jr. Effects of topically applied capsaicin on moderate and severe psoriasis vulgaris. *J Am Acad Dermatol* 1986; 15: 504–507.
 98. Breneman DL, Cardone JS, Blumsack RF, Lather RM, Searle EA, Pollack VE. Topical capsaicin for treatment of hemodialysis-related pruritus. *J Am Acad Dermatol* 1992; 26: 91–94.
 99. Tarng DC, Cho YL, Liu HN, Huang TP. Hemodialysis-related pruritus: a double-blind, placebo-controlled, crossover study of capsaicin 0.025% cream. *Nephron* 1996; 72: 617–622.
 100. Reimann S, Luger T, Metz D. Topische Anwendung von Capsaicin in der Dermatologie zur Therapie von Juckreiz und Schmerz. *Hautarzt* 2000; 51: 164–172.
 101. Szeimies RM, Stolz W, Wlotzke U, Korting HC, Landthaler M. Successful treatment of hydroxyethyl starch-induced pruritus with topical capsaicin. *Br J Dermatol* 1994; 131: 380–382.
 102. Hoogenberg K, Tupker RA, van Essen LH, Smit AJ, Kaltenberg CG. Successful treatment of ulcerating livedo reticularis with infusions of prostacyclin. *Br J Dermatol* 1992; 127: 64–66.
 103. Tupker RA, Coenraads PJ, van der Meer JB. Treatment of prurigo nodularis, chronic prurigo and neurodermatitis circumscripta with topical capsaicin. *Acta Derm Venereol* 1992; 72: 463.
 104. Ständer S, Luger T, Metz D. Treatment of prurigo nodularis with topical capsaicin. *J Am Acad Dermatol* 2001; 44: 471–478.
 105. Lotti T, Teofoli P, Tsampou D. Treatment of aquagenic pruritus with topical capsaicin cream. *J Am Acad Dermatol* 1994; 30: 232–235.
 106. Kirby B, Rogers S. Treatment of PUVA itch with capsaicin. *Br J Dermatol* 1997; 137: 152.
 107. Rukwied R, Watkinson A, McGlone F, Dvorak M. Cannabinoid agonists attenuate capsaicin-induced responses in human skin. *Pain* 2003; 102: 283–288.
 108. Dvorak M, Watkinson A, McGlone F, Rukwied R. Histamine induced responses are attenuated by a cannabinoid receptor agonist in human skin. *Inflamm Res* 2003; 52: 238–245.
 109. Ständer S, Reinhardt HW, Luger TA. Topische Cannabinoidagonisten. Eine effektive, neue Möglichkeit zur Behandlung von chronischem Pruritus. *Hautarzt* 2006; 57: 801–807.
 110. Szepietowski JC, Szepietowski T, Reich A. Efficacy and tolerance of the cream containing structured physiological lipids with endocannabinoids in the treatment of uremic pruritus: a preliminary study. *Acta Dermatovenerol Croat* 2005; 13: 97–103.

111. Eberlein B, Eicke C, Reinhardt HW, Ring J. Adjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATOPA study). *J Eur Acad Dermatol Venereol* 2008; 22: 73–82.
112. Phan NQ, Siepmann D, Gralow I, Ständer S. Adjuvant topical therapy with a cannabinoid receptor agonist in facial postherpetic neuralgia. *J Dtsch Dermatol Ges* 2010; 8: 88–91.
113. Ständer S, Luger TA. Antipruritische Wirkung von Pimecrolimus und Tacrolimus. *Hautarzt* 2003; 54: 413–417.
114. Fleischer AB, Jr., Boguniewicz M. An approach to pruritus in atopic dermatitis: a critical systematic review of the tacrolimus ointment literature. *J Drugs Dermatol* 2010; 9: 488–498.
115. Wollina U, Hansel G, Koch A, Abdel-Naser MB. Topical pimecrolimus for skin disease other than atopic dermatitis. *Expert Opin Pharmacother* 2006; 7: 1967–1975.
116. Simpson D, Noble S. Tacrolimus ointment: a review of its use in atopic dermatitis and its clinical potential in other inflammatory skin conditions. *Drugs* 2005; 65: 827–858.
117. Goldstein AT, Creasey A, Pfau R, Phillips D, Burrows LJ. A double-blind, randomized controlled trial of clobetasol versus pimecrolimus in patients with vulvar lichen sclerosus. *J Am Acad Dermatol* 2011; 64: 99–104.
118. Papp KA, Papp A, Dahmer B, Clark CS. Single-blind, randomized controlled trial evaluating the treatment of facial seborrheic dermatitis with hydrocortisone 1% ointment compared with tacrolimus 0.1% ointment in adults. *J Am Acad Dermatol* 2011 (Epub ahead of print).
119. Kuhn A, Gensch K, Faust M, Schneider SW, Bonsmann G, Gaebelein-Wissing N, et al. Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double-blind, vehicle-controlled trial. *J Am Acad Dermatol* 2011; 65: 1–2.
120. Barikbin B, Givrad S, Yousefi M, Eskandari F. Pimecrolimus 1% cream versus betamethasone 17-valerate 0.1% cream in the treatment of facial discoid lupus erythematosus: a double-blind, randomized pilot study. *Clin Exp Dermatol* 2009; 34: 776–780.
121. Suys E. Randomized study of topical tacrolimus ointment as possible treatment for resistant idiopathic pruritus ani. *J Am Acad Dermatol* 2012; 66: 327–328.
122. Ang-Tiu CU, Meghrajani CF, Maano CC. Pimecrolimus 1% cream for the treatment of seborrheic dermatitis: a systematic review of randomized controlled trials. *Expert Rev Clin Pharmacol* 2012; 5: 91–97.
123. Aguilar-Bernier M, Bassas-Vila J, Sanz-Munoz C, Miranda-Romero A. Successful treatment of pruritus with topical tacrolimus in a patient with primary biliary cirrhosis. *Br J Dermatol* 2005; 152: 808–809.
124. Pauli-Magnus C, Klumpp S, Alschner DM, Kuhlmann U, Mettang T. Short-term efficacy of tacrolimus ointment in severe uremic pruritus. *Perit Dial Int* 2000; 20: 802–803.
125. Kuypers DR, Claes K, Evenepoel P, Maes B, Vanrenterghem Y. A prospective proof of concept study of the efficacy of tacrolimus ointment on uraemic pruritus (UP) in patients on chronic dialysis therapy. *Nephrol Dial Transplant* 2004; 19: 1895–1901.
126. Ghorbani AR, Feily A, Khalili A, Dormanesh B. Lack of efficacy of topical calcineurin inhibitor pimecrolimus 1% on pruritus of severely uremic patients: a randomized double-blind study in 60 patients. *Dermatitis* 2011; 22: 167–168.
127. Duque MI, Yosipovitch G, Fleischer AB, Jr., Willard J, Freedman BI. Lack of efficacy of tacrolimus ointment 0.1% for treatment of hemodialysis-related pruritus: a randomized, double-blind, vehicle-controlled study. *J Am Acad Dermatol* 2005; 52: 519–521.
128. Ständer S, Schuermeyer-Horst F, Luger T, Weisshaar EW. Treatment of pruritic diseases with topical calcineurin inhibitors. *The Clin Risk* 2006; 2: 213–218.
129. Yosipovitch G, Sugeng MW, Chan YH, Goon A, Ngim S, Goh CL. The effect of topically applied aspirin on localized circumscribed neurodermatitis. *J Am Acad Dermatol* 2001; 45: 910–913.
130. Thomsen JS, Benfeldt E, Jensen SB, Serup J, Menne T. Topically applied aspirin decreases histamine-induced wheal and flare reactions in normal and SLS-inflamed skin, but does not decrease itch. A randomized, double-blind and placebo-controlled human study. *Acta Derm Venereol* 2002; 82: 30–35.
131. Drake LA, Fallon JD, Sober A. Relief of pruritus in patients with atopic dermatitis after treatment with topical doxepin cream. The Doxepin Study Group. *J Am Acad Dermatol* 1994; 31: 613–616.
132. Drake LA, Millikan LE. The antipruritic effect of 5% doxepin cream in patients with eczematous dermatitis. Doxepin Study Group. *Arch Dermatol* 1995; 131: 1403–1408.
133. Greenberg JH. Allergic contact dermatitis from topical doxepin. *Contact dermatitis* 1995; 33: 281.
134. Shelley WB, Shelley ED, Talanin NY. Self-potentiating allergic contact dermatitis caused by doxepin hydrochloride cream. *J Am Acad Dermatol* 1996; 34: 143–144.
135. Bonnel RA, La Grenade L, Karwoski CB, Beitz JG. Allergic contact dermatitis from topical doxepin: Food and Drug Administration's postmarketing surveillance experience. *J Am Acad Dermatol* 2003; 48: 294–296.
136. Welsh AL. *Dermatologist's handbook*. Curtis CA, editor. Springfield, Illinois: Charles C Thomas. Publisher; 1955.
137. Green BG, Schoen KL. Thermal and nociceptive sensations from menthol and their suppression by dynamic contact. *Behav Brain Res* 2007; 176: 284–291.
138. Macpherson LJ, Hwang SW, Miyamoto T, Dubin AE, Patapoutian A, Story GM. More than cool: promiscuous relationships of menthol and other sensory compounds. *Mol Cell Neurosci* 2006; 32: 335–343.
139. Czarnetzki BM, Brechtel B, Braun-Falco O, Christophers E, Schopf E, Reckers-Czaschka R, et al. Topical tiacrilast, a potent mast cell degranulation inhibitor, does not improve adult atopic eczema. *Dermatology* 1993; 187: 112–114.
140. Haider SA. Treatment of atopic eczema in children: clinical trial of 10% sodium cromoglycate ointment. *BMJ* 1977; 1: 1570–1572.
141. Stainer R, Matthews S, Arshad SH, McDonald S, Robinson J, Schapira C, et al. Efficacy and acceptability of a new topical skin lotion of sodium cromoglycate (Altoderm) in atopic dermatitis in children aged 2–12 years: a double-blind, randomized, placebo-controlled trial. *Br J Dermatol* 2005; 152: 334–341.
142. O'Donoghue M, Tharp MD. Antihistamines and their role as antipruritics. *Dermatol Ther* 2005; 18: 333–340.
143. Asero R. Chronic unremitting urticaria: is the use of antihistamines above the licensed dose effective? A preliminary study of cetirizine at licensed and above-licensed doses. *Clin Exp Dermatol* 2007; 32: 34–38.
144. Schulz S, Metz M, Siepmann D, Luger TA, Maurer M, Ständer S. Antipruritische Wirksamkeit einer hochdosierten Antihistaminika-Therapie: Ergebnisse einer retrospektiv analysierten Fallserie. *Hautarzt* 2009; 60: 564–568.
145. Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic eczema. *Health Technol Assess* 2000; 4: 1–191.
146. Rhoades RB, Leifer KN, Cohan R, Wittig HJ. Suppression of histamine-induced pruritus by three antihistaminic

- drugs. *J Allergy Clin Immunol* 1975; 55: 180–185.
147. Arnold AJ, Simpson JG, Jones HE, Ahmed AR. Suppression of histamine-induced pruritus by hydroxyzine and various neuroleptics. *J Am Acad Dermatol* 1979; 1: 509–512.
 148. Paul E, Bodeker RH. Treatment of chronic urticaria with terfenadine and ranitidine. A randomized double-blind study in 45 patients. *Eur J Clin Pharmacol* 1986; 31: 277–280.
 149. Nettis E, Colanardi MC, Paradiso MT, Ferrannini A. Desloratadine in combination with montelukast in the treatment of chronic urticaria: a randomized, double-blind, placebo-controlled study. *Clin Exp Allergy* 2004; 34: 1401–1407.
 150. Francos GC, Kauh YC, Gittlen SD, Schulman ES, Besarab A, Goyal S, et al. Elevated plasma histamine in chronic uremia. Effects of ketotifen on pruritus. *Int J Dermatol* 1991; 30: 884–889.
 151. Rosner MH. Cromolyn sodium: a potential therapy for uremic pruritus? *Hemodial Int* 2006; 10: 189–192.
 152. Leven A, Naysmith A, Pickens S, Pottage A. Sodium cromoglycate and Hodgkin's pruritus. *BMJ* 1977; 2: 896.
 153. Streit M, Von Felbert V, Braathen LR. Pruritus sine materia. Pathophysiologie, Abklärung und Therapie. *Hautarzt* 2002; 53: 830–849.
 154. Fjellner B, Hägermark O. Potentiation of histamine-induced itch and flare responses in human skin by the enkephalin analogue FK-33-824, beta-endorphin and morphine. *Arch Dermatol Res* 1982; 274: 29–37.
 155. Phan NQ, Lotts T, Antal A, Bernhard JD, Ständer S. Systemic kappa opioid receptor agonists in the treatment of chronic pruritus: a literature review. *Acta Derm Venereol* 2012; 92: 555–560.
 156. Bergasa NV, Alling DW, Talbot TL, Swain MG, Yurdaydin C, Turner ML, et al. Effects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial. *Ann Intern Med* 1995; 123: 161–167.
 157. Bergasa NV, Alling DW, Talbot TL, Wells MC, Jones EA. Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: a controlled study. *J Am Acad Dermatol* 1999; 41: 431–434.
 158. Bergasa NV, Talbot TL, Alling DW, Schmitt JM, Walker EC, Baker BL, et al. A controlled trial of naloxone infusions for the pruritus of chronic cholestasis. *Gastroenterology* 1992; 102: 544–549.
 159. Wolfhagen FH, Sternieri E, Hop WC, Vitale G, Bertolotti M, Van Buuren HR. Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study. *Gastroenterology* 1997; 113: 1264–1269.
 160. Phan NQ, Bernhard JD, Luger TA, Ständer S. Antipruritic treatment with systemic μ -opioid receptor antagonists. A review. *J Am Acad Dermatol* 2010; 63: 680–688.
 161. Banerji D, Fox R, Seleznick M, Lockey R. Controlled antipruritic trial of nalmefene in chronic urticaria and atopic dermatitis. *J Allergy Clin Immunol* 1988; 81: 252.
 162. Monroe EW. Efficacy and safety of nalmefene in patients with severe pruritus caused by chronic urticaria and atopic dermatitis. *J Am Acad Dermatol* 1989; 21: 135–136.
 163. Ghura HS, Patterson AD, Carmichael AJ. Naltrexone in the treatment of renal itch. *Br J Dermatol* 1998; 139: 139.
 164. Kumagai H, Ebata T, Takamori K, Muramatsu T, Nakamoto H, Suzuki H. Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled study. *Nephrol Dial Transplant* 2010; 25: 1251–1257.
 165. Misery L. Gabapentin in dermatology. *Dermatology* 2005; 211: 79–80.
 166. Argoff CE, Katz N, Backonja M. Treatment of postherpetic neuralgia: a review of therapeutic options. *J Pain Symptom Manage* 2004; 28: 396–411.
 167. Kanitakis J. Brachioradial pruritus: report of a new case responding to gabapentin. *Eur J Dermatol* 2006; 16: 311–312.
 168. Demierre MF, Taverna J. Mirtazapine and gabapentin for reducing pruritus in cutaneous T-cell lymphoma. *J Am Acad Dermatol* 2006; 55: 543–544.
 169. Mendham JE. Gabapentin for the treatment of itching produced by burns and wound healing in children: a pilot study. *Burns* 2004; 30: 851–853.
 170. Gunal AI, Ozalp G, Yoldas TK, Gunal SY, Kirciman E, Celiker H. Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial. *Nephrol Dial Transplant* 2004; 19: 3137–3139.
 171. Bergasa NV, McGee M, Ginsburg IH, Engler D. Gabapentin in patients with the pruritus of cholestasis: a double-blind, randomized, placebo-controlled trial. *Hepatology* 2006; 44: 1317–1323.
 172. Vila T, Gommer J, Scates AC. Role of gabapentin in the treatment of uremic pruritus. *Ann Pharmacother* 2008; 42: 1080–1084.
 173. Razeghi E, Eskandari D, Ganji MR, Meysamie AP, Togha M, Khashayar P. Gabapentin and uremic pruritus in hemodialysis patients. *Ren Fail* 2009; 31: 85–90.
 174. Porzio G, Aielli F, Verna L, Porto C, Tudini M, Cannita K, et al. Efficacy of pregabalin in the management of cetuximab-related itch. *J Pain Symptom Manage* 2006; 32: 397–398.
 175. Ehrchen J, Ständer S. Pregabalin in the treatment of chronic pruritus. *J Am Acad Dermatol* 2008; 58: 36–37.
 176. Aperis G, Paliouras C, Zervos A, Arvanitis A, Alivanis P. The use of pregabalin in the treatment of uraemic pruritus in haemodialysis patients. *J Ren Care* 2010; 36: 180–185.
 177. Paus R, Schmelz M, Biro T, Steinhoff M. Frontiers in pruritus research: scratching the brain for more effective itch therapy. *J Clin Invest* 2006; 116: 1174–1186.
 178. Zyllicz Z, Krajnik M, Sorge AA, Costantini M. Paroxetine in the treatment of severe non-dermatological pruritus: a randomized, controlled trial. *J Pain Symptom Manage* 2003; 26: 1105–1112.
 179. Davis MP, Frandsen JL, Walsh D, Andresen S, Taylor S. Mirtazapine for pruritus. *J Pain Symptom Manage* 2003; 25: 288–291.
 180. Shohrati M, Tajik A, Harandi AA, Davoodi SM, Akmasi M. Comparison of hydroxyzine and doxepin in treatment of pruritus due to sulfur mustard. *Skinmed* 2007; 6: 70–72.
 181. Tefferi A, Fonseca R. Selective serotonin reuptake inhibitors are effective in the treatment of polycythemia vera-associated pruritus. *Blood* 2002; 99: 2627.
 182. Zyllicz Z, Smits C, Krajnik M. Paroxetine for pruritus in advanced cancer. *J Pain Symptom Manage* 1998; 16: 121–124.
 183. Weisshaar E. Intractable chronic pruritus in a 67-year-old man. *Acta Derm Venereol* 2008; 88: 488–490.
 184. Biondi M, Arcangeli T, Petrucci RM. Paroxetine in a case of psychogenic pruritus and neurotic excoriations. *Psychother Psychosom* 2000; 69: 165–166.
 185. Mazzatenta C, Peonia G, Martini P. Pruritus induced by interruption of paroxetine therapy. *Br J Dermatol* 2004; 150: 787.
 186. Ständer S, Bockenholt B, Schurmeyer-Horst F, Weishaupt C, Heuft G, Luger TA, et al. Treatment of chronic pruritus with the selective serotonin re-uptake inhibitors paroxetine

- and fluvoxamine: results of an open-labelled, two-arm proof-of-concept study. *Acta Derm Venereol* 2009; 89: 45–51.
187. Mayo MJ, Handem I, Saldana S, Jacobe H, Getachew Y, Rush AJ. Sertraline as a first-line treatment for cholestatic pruritus. *Hepatology* 2007; 45: 666–674.
 188. Schworer H, Hartmann H, Ramadori G. Relief of cholestatic pruritus by a novel class of drugs: 5-hydroxytryptamine type 3 (5-HT₃) receptor antagonists: effectiveness of ondansetron. *Pain* 1995; 61: 33–37.
 189. Schworer H, Ramadori G. Improvement of cholestatic pruritus by ondansetron. *Lancet* 1993; 341: 1277.
 190. Schworer H, Ramadori G. Treatment of pruritus: a new indication for serotonin type 3 receptor antagonists. *Clin Investig* 1993; 71: 659–662.
 191. Andrews PA, Quan V, Ogg CS. Ondansetron for symptomatic relief in terminal uraemia. *Nephrol Dial Transplant* 1995; 10: 140.
 192. Jones EA. Relief from profound fatigue associated with chronic liver disease by long-term ondansetron therapy. *Lancet* 1999; 354: 397.
 193. Raderer M, Muller C, Scheithauer W. Ondansetron for pruritus due to cholestasis. *N Engl J Med* 1994; 330: 1540.
 194. Albares MP, Betlloch I, Guijarro J, Vergara G, Pascual JC, Botella R. Severe pruritus in a haemodialysed patient: dramatic improvement with granisetron. *Br J Dermatol* 2003; 148: 376–377.
 195. Muller C, Pongratz S, Pidlich J, Penner E, Kaider A, Schemper M, et al. Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial. *Eur J Gastroenterol Hepatol* 1998; 10: 865–870.
 196. O'Donohue JW, Haigh C, Williams R. Ondansetron in the treatment of cholestasis: a randomised controlled trial. *Gastroenterology* 1997; 112: A1349.
 197. Larijani GE, Goldberg ME, Rogers KH. Treatment of opioid-induced pruritus with ondansetron: report of four patients. *Pharmacotherapy* 1996; 16: 958–960.
 198. Borgeat A, Stirnemann HR. Ondansetron is effective to treat spinal or epidural morphine-induced pruritus. *Anesthesiology* 1999; 90: 432–436.
 199. Kjellberg F, Tramer MR. Pharmacological control of opioid-induced pruritus: a quantitative systematic review of randomized trials. *Eur J Anaesthesiol* 2001; 18: 346–357.
 200. Balaskas EV, Bamihas GI, Karamouzis M, Voyiatzis G, Tourkantonis A. Histamine and serotonin in uremic pruritus: effect of ondansetron in CAPD-pruritic patients. *Nephron* 1998; 78: 395–402.
 201. Weisshaar E, Dunker N, Rohl FW, Gollnick H. Antipruritic effects of two different 5-HT₃ receptor antagonists and an antihistamine in haemodialysis patients. *Exp Dermatol* 2004; 13: 298–304.
 202. Ashmore SD, Jones CH, Newstead CG, Daly MJ, Chrystyn H. Ondansetron therapy for uremic pruritus in hemodialysis patients. *Am J Kidney Dis* 2000; 35: 827–831.
 203. Murphy M, Reaich D, Pai P, Finn P, Carmichael AJ. A randomized, placebo-controlled, double-blind trial of ondansetron in renal itch. *Br J Dermatol* 2003; 148: 314–317.
 204. Daly BM, Shuster S. Antipruritic action of thalidomide. *Acta Derm Venereol* 2000; 80: 24–25.
 205. van den Broek H. Treatment of prurigo nodularis with thalidomide. *Arch Dermatol* 1980; 116: 571–572.
 206. Arrese JE, Dominguez-Soto L, Hojyo-Tomoka MT, Vega-Memije E, Cortes-Franco R, Guevara E, et al. Effectors of inflammation in actinic prurigo. *J Am Acad Dermatol* 2001; 44: 957–961.
 207. Winkelmann RK, Connolly SM, Doyle JA, Padilha-Goncalves A. Thalidomide treatment of prurigo nodularis. *Acta Derm Venereol* 1984; 64: 412–417.
 208. Johnke H, Zachariae H. Thalidomide treatment of prurigo nodularis. *Ugeskr Laeger* 1993; 155: 3028–3030.
 209. Ferrandiz C, Carrascosa JM, Just M, Bielsa I, Ribera M. Sequential combined therapy with thalidomide and narrow-band (TL01) UVB in the treatment of prurigo nodularis. *Dermatology* 1997; 195: 359–361.
 210. Maurer T, Poncet A, Berger T. Thalidomide treatment for prurigo nodularis in human immunodeficiency virus-infected subjects: efficacy and risk of neuropathy. *Arch Dermatol* 2004; 140: 845–849.
 211. Silva SR, Viana PC, Lugon NV, Hoette M, Ruzany F, Lugon JR. Thalidomide for the treatment of uremic pruritus: a crossover randomized double-blind trial. *Nephron* 1994; 67: 270–273.
 212. Gaspari A. Thalidomide neurotoxicity in dermatological patients: the next „STEP“. *J Invest Dermatol* 2002; 119: 987–988.
 213. van Joost T, Stolz E, Heule F. Efficacy of low-dose cyclosporine in severe atopic skin disease. *Arch Dermatol* 1987; 123: 166–167.
 214. Wahlgren CF, Scheynius A, Hägermark O. Antipruritic effect of oral cyclosporin A in atopic dermatitis. *Acta Derm Venereol* 1990; 70: 323–329.
 215. Berth-Jones J, Smith SG, Graham-Brown RA. Nodular prurigo responds to cyclosporin. *Br J Dermatol* 1995; 132: 795–799.
 216. Siepmann D, Luger TA, Ständer S. Antipruritic effect of cyclosporine microemulsion in prurigo nodularis: results of a case series. *J Dtsch Dermatol Ges* 2008; 6: 941–946.
 217. Teofoli P, De Pita O, Frezzolini A, Lotti T. Antipruritic effect of oral cyclosporin A in essential senile pruritus. *Acta Derm Venereol* 1998; 78: 232.
 218. Calikoglu E, Anadolu R. Management of generalized pruritus in dominant dystrophic epidermolysis bullosa using low-dose oral cyclosporin. *Acta Derm Venereol* 2002; 82: 380–382.
 219. Fusaro M, Munaretto G, Spinello M, Gallieni M. Regression of uraemic pruritus by cyclosporin treatment in a haemodialysis patient. *Nephrol Dial Transplant* 2004; 19: 1338–1339.
 220. Vincenzi B, Tonini G, Santini D. Aprepitant for erlotinib-induced pruritus. *N Engl J Med* 2010; 363: 397–398.
 221. Vincenzi B, Fratto ME, Santini D, Tonini G. Aprepitant against pruritus in patients with solid tumours. *Support Care Cancer* 2010; 18: 1229–1230.
 222. Torres T, Fernandes I, Selores M, Alves R, Lima M. Aprepitant: Evidence of its effectiveness in patients with refractory pruritus continues. *J Am Acad Dermatol* 2012; 66: 14–15.
 223. Booken N, Heck M, Nicolay JP, Klemke CD, Goerdts S, Utikal J. Oral aprepitant in the therapy of refractory pruritus in erythrodermic cutaneous T-cell lymphoma. *Br J Dermatol* 2011; 164: 665–667.
 224. Ständer S, Siepmann D, Herrgott I, Sunderkotter C, Luger TA. Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy. *PLoS one* 2010; 5: e10968.
 225. Rivard J, Lim HW. Ultraviolet phototherapy for pruritus. *Dermatol Ther* 2005; 18: 344–354.
 226. Jekler J, Larko O. UVB phototherapy of atopic dermatitis. *Br J Dermatol* 1988; 119: 697–705.
 227. Reynolds NJ, Franklin V, Gray JC, Diffey BL, Farr PM. Narrow-band ultraviolet B and broad-band ultraviolet A phototherapy in adult atopic eczema: a randomised con-

- trolled trial. *Lancet* 2001; 357: 2012–2016.
228. Jekler J, Larko O. UVA solarium versus UVB phototherapy of atopic dermatitis: a paired-comparison study. *Br J Dermatol* 1991; 125: 569–572.
 229. Legat FJ, Hofer A, Brabek E, Quehenberger F, Kerl H, Wolf P. Narrowband UV-B vs medium-dose UV-A1 phototherapy in chronic atopic dermatitis. *Arch Dermatol* 2003; 139: 223–224.
 230. Gambichler T, Hyun J, Sommer A, Stucker M, Altmeyer P, Kreuter A. A randomised controlled trial on photo(chemo)therapy of subacute prurigo. *Clin Exp Dermatol* 2006; 31: 348–353.
 231. Szepletowski JC, Morita A, Tsuji T. Ultraviolet B induces mast cell apoptosis: a hypothetical mechanism of ultraviolet B treatment for uraemic pruritus. *Med Hypotheses* 2002; 58: 167–170.
 232. Wallengren J, Sundler F. Phototherapy reduces the number of epidermal and CGRP-positive dermal nerve fibres. *Acta Derm Venereol* 2004; 84: 111–115.
 233. Saltzer EJ, Grove G. Relief from uremic pruritus: a therapeutic approach. *Cutis* 1975; 16: 298–299.
 234. Gilchrist BA, Rowe JW, Brown RS, Steinman TI, Arndt KA. Relief of uremic pruritus with ultraviolet phototherapy. *N Engl J Med* 1977; 297: 136–138.
 235. Taylor R, Taylor AE, Diffey BL, Hindson TC. A placebo-controlled trial of UV-A phototherapy for the treatment of uraemic pruritus. *Nephron* 1983; 33: 14–16.
 236. Berne B, Vahlquist A, Fischer T, Danielson BG, Berne C. UV treatment of uraemic pruritus reduces the vitamin A content of the skin. *Eur J Clin Invest* 1984; 14: 203–206.
 237. Gilchrist BA, Rowe JW, Brown RS, Steinman TI, Arndt KA. Ultraviolet phototherapy of uremic pruritus. Long-term results and possible mechanism of action. *Ann Intern Med* 1979; 91: 17–21.
 238. Ada S, Seckin D, Budakoglu I, Ozdemir FN. Treatment of uremic pruritus with narrowband ultraviolet B phototherapy: an open pilot study. *J Am Acad Dermatol* 2005; 53: 149–151.
 239. Seckin D, Demircay Z, Akin O. Generalized pruritus treated with narrowband UVB. *Int J Dermatol* 2007; 46: 367–370.
 240. Hsu MM, Yang CC. Uraemic pruritus responsive to broadband ultraviolet (UV) B therapy does not readily respond to narrowband UVB therapy. *Br J Dermatol* 2003; 149: 888–889.
 241. Baldo A, Sammarco E, Plaitano R, Martinelli V, Monfrecola. Narrowband (TL-01) ultraviolet B phototherapy for pruritus in polycythaemia vera. *Br J Dermatol* 2002; 147: 979–981.
 242. Jahn S, von Kobyletzki G, Behrens S, Röchling A, Altmeyer P, Kerscher M. Erfolgreiche Behandlung des aquagenen Pruritus mit PUVA-Bad-Photochemotherapie. *Z Hautkr* 1997; 72: 821–824.
 243. Martinez-Escribano JA, Quecedo E, De la Cuadra J, Frias J, Sanchez-Pedreno P, Aliaga A. Treatment of aquagenic urticaria with PUVA and astemizole. *J Am Acad Dermatol* 1997; 36: 118–119.
 244. Menage HD, Norris PG, Hawk JL, Graves MW. The efficacy of psoralen photochemotherapy in the treatment of aquagenic pruritus. *Br J Dermatol* 1993; 129: 163–165.
 245. Xifra A, Carrascosa JM, Ferrandiz C. Narrow-band ultraviolet B in aquagenic pruritus. *Br J Dermatol* 2005; 153: 1233–1234.
 246. Lim HW, Vallurupalli S, Meola T, Soter NA. UVB phototherapy is an effective treatment for pruritus in patients infected with HIV. *J Am Acad Dermatol* 1997; 37: 414–417.
 247. Kaptanoglu AF, Oskay T. Ultraviolet B treatment for pruritus in Hodgkin's lymphoma. *J Eur Acad Dermatol Venereol* 2003; 17: 489–490.
 248. Pavlovsky M, Baum S, Shpiro D, Pavlovsky L, Pavlotsky F. Narrow band UVB: is it effective and safe for paediatric psoriasis and atopic dermatitis? *J Eur Acad Dermatol Venereol* 2011; 25: 727–729.
 249. Rosenbaum MS, Ayllon T. The behavioral treatment of neurodermatitis through habit-reversal. *Behav Res Ther* 1981; 19: 313–318.
 250. Gieler U, Kupfer J, Niemeier V, Brosig B, Stangier U. Atopic eczema prevention programs – a new therapeutic concept for secondary prevention. *Dermatol Psychosom* 2000; 1: 138–147.
 251. Staab D, von Rueden U, Kehrt R, Erhart M, Wenninger K, Kamtsiuris P, et al. Evaluation of a parental training program for the management of childhood atopic dermatitis. *Pediatr Allergy Immunol* 2002; 13: 84–90.
 252. Stangier U, Ehlers A, Gieler U. Predicting long-term outcome in group treatment of atopic dermatitis. *Psychother Psychosom* 2004; 73: 293–301.
 253. Evers AW, Duller P, de Jong EM, Otero ME, Verhaak CM, van der Valk PG, et al. Effectiveness of a multidisciplinary itch-coping training programme in adults with atopic dermatitis. *Acta Derm Venereol* 2009; 89: 57–63.
 254. Bathe A, Mattered U, Dewald M, Grande T, Weisshaar E. Educational multidisciplinary trainingprogramme for patients with chronic pruritus. *Acta Derm Venereol* 2009; 89: 498–501.
 255. Hoegl L, Fichter M, Plewig G. Stationäre Verhaltensmedizin bei chronischen Hautkrankheiten. *Hautarzt* 1998; 49: 270–275.
 256. Lange S, Zschocke I, Langhardt S, Amon U, Augustin M. Effekte kombinierter therapeutischer Massnahmen bei Patienten mit Psoriasis und atopischer Dermatitis. *Hautarzt* 1999; 50: 791–797.
 257. Gupta MA. Evaluation and treatment of „psychogenic“ pruritus and self-excoriation. *J Am Acad Dermatol* 1995; 32: 532–533.
 258. Arnold LM, Auchenbach MB, McElroy SL. Psychogenic excoriation. Clinical features, proposed diagnostic criteria, epidemiology and approaches to treatment. *CNS Drugs* 2001; 15: 351–359.
 259. Phillips LG, Robson MC. Pruritus in burns. Comments from Detroit Receiving Hospital, Detroit, Michigan. *J Burn Care Rehabil* 1988; 9: 308–309.
 260. Phillips KA. Pharmacologic treatment of body dysmorphic disorder: review of the evidence and a recommended treatment approach. *CNS Spectr* 2002; 7: 453–460, 63.
 261. Chen YC, Chiu WT, Wu MS. Therapeutic effect of topical gamma-linolenic acid on refractory uremic pruritus. *Am J Kidney Dis* 2006; 48: 69–76.
 262. Che-Yi C, Wen CY, Min-Tsung K, Chiu-Ching H. Acupuncture in haemodialysis patients at the Quchi (LI11) acupoint for refractory uraemic pruritus. *Nephrol Dial Transplant* 2005; 20: 1912–1915.
 263. De Marchi S, Cecchin E, Villalta D, Sepiacci G, Santini G, Bartoli E. Relief of pruritus and decreases in plasma histamine concentrations during erythropoietin therapy in patients with uremia. *N Engl J Med* 1992; 326: 969–974.
 264. Goulis J, Leandro G, Burroughs AK. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. *Lancet* 1999; 354: 1053–1060.
 265. Ghent CN, Carruthers SG. Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial. *Gastroenterology* 1988; 94:

- 488–493.
266. Terg R, Coronel E, Sorda J, Munoz AE, Findor J. Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study. *J Hepatol* 2002; 37: 717–722.
 267. McCormick PA, Scott F, Epstein O, Burroughs AK, Scheuer PJ, McIntyre N. Thalidomide as therapy for primary biliary cirrhosis: a double-blind placebo controlled pilot study. *J Hepatol* 1994; 21: 496–499.
 268. Raiford DS. Pruritus of chronic cholestasis. *QJM* 1995; 88: 603–607.
 269. Walt RP, Daneshmend TK, Fellows IW, Toghil PJ. Effect of stanazolol on itching in primary biliary cirrhosis. *BMJ* 1988; 296: 607.
 270. Fleischer AB, Jr. The clinical management of itching. New York, London: Parthenon Publishing; 2000.
 271. Bergasa NV, Link MJ, Keogh M, Yaroslavsky G, Rosenthal RN, McGee M. Pilot study of bright-light therapy reflected toward the eyes for the pruritus of chronic liver disease. *Am J Gastroenterol* 2001; 96: 1563–1570.
 272. Epstein MP, Kaplan MM. A pilot study of etanercept in the treatment of primary sclerosing cholangitis. *Dig Dis Sci* 2004; 49: 1–4.
 273. Doria C, Mandala L, Smith J, Vitale CH, Lauro A, Gruttadauria S, et al. Effect of molecular adsorbent recirculating system in hepatitis C virus-related intractable pruritus. *Liver Transpl* 2003; 9: 437–443.
 274. Mullhaupt B, Kullak-Ublick GA, Ambuhl PM, Stocker R, Renner EL. Successful use of the Molecular Adsorbent Recirculating System (MARS) in a patient with primary biliary cirrhosis (PBC) and treatment refractory pruritus. *Hepatol Res* 2003; 25: 442–446.
 275. Bellmann R, Graziadei IW, Feistritz C, Schwaighofer H, Stellaard F, Sturm E, et al. Treatment of refractory cholestatic pruritus after liver transplantation with albumin dialysis. *Liver Transpl* 2004; 10: 107–114.
 276. Bellmann R, Feistritz C, Zoller H, Graziadei IW, Schwaighofer H, Propst A, et al. Treatment of intractable pruritus in drug induced cholestasis with albumin dialysis: a report of two cases. *ASAIO J* 2004; 50: 387–391.
 277. Acevedo Ribo M, Moreno Planas JM, Sanz Moreno C, Rubio Gonzalez EE, Rubio Gonzalez E, Bouldosa Grana E, et al. Therapy of intractable pruritus with MARS. *Transplant Proc* 2005; 37: 1480–1481.
 278. Montero JL, Pozo JC, Barrera P, Fraga E, Costan G, Dominguez JL, et al. Treatment of refractory cholestatic pruritus with molecular adsorbent recirculating system (MARS). *Transplant Proc* 2006; 38: 2511–2513.
 279. Neuberger J. Liver Transplantation for Cholestatic Liver Disease. *Curr Treat Options Gastroenterol* 2003; 6: 113–121.
 280. Ständer S, Steinhoff M. Pathophysiology of pruritus in atopic dermatitis: an overview. *Exp Dermatol* 2002; 11: 12–24.
 281. Brune A, Metze D, Luger TA, Ständer S. Antipruritische Therapie mit dem oralen Opiatrezeptorantagonisten Naltrexon. Offene, nicht placebokontrollierte Anwendung bei 133 Patienten. *Hautarzt* 2004; 55: 1130–1136.
 282. Fjellner B, Hagermark O. Pruritus in polycythemia vera: treatment with aspirin and possibility of platelet involvement. *Acta Derm Venereol* 1979; 59: 505–512.
 283. Easton P, Galbraith PR. Cimetidine treatment of pruritus in polycythemia vera. *The N Engl J Med* 1978; 299: 1134.
 284. Weick JK, Donovan PB, Najean Y, Dresch C, Pisciotta AV, Cooperberg AA, et al. The use of cimetidine for the treatment of pruritus in polycythemia vera. *Arch Intern Med* 1982; 142: 241–242.
 285. Fitzsimons EJ, Dagg JH, McAllister EJ. Pruritus of polycythaemia vera: a place for pizotifen? *BMJ* 1981; 283: 277.
 286. Chanarin I, Szur L. Letter: Relief of intractable pruritus in polycythaemia rubra vera with cholestyramine. *Br J Haematol* 1975; 29: 669–670.
 287. Swerlick RA. Photochemotherapy treatment of pruritus associated with polycythemia vera. *J Am Acad Dermatol* 1985; 13: 675–677.
 288. Jeanmougin M, Rain JD, Najean Y. Efficacy of photochemotherapy on severe pruritus in polycythemia vera. *Ann Hematol* 1996; 73: 91–93.
 289. Tinegate H, McLelland J. Transcutaneous electrical nerve stimulation may improve pruritus associated with haematological disorders. *Clin Lab Haematol* 2002; 24: 389–390.
 290. de Wolf JT, Hendriks DW, Egger RC, Esselink MT, Halie MR, Vellenga E. Alpha-interferon for intractable pruritus in polycythaemia vera. *Lancet* 1991; 337: 241.
 291. Muller EW, de Wolf JT, Egger R, Wijermans PW, Huijgens PC, Halie MR, et al. Long-term treatment with interferon-alpha 2b for severe pruritus in patients with polycythaemia vera. *Br J Haematol* 1995; 89: 313–318.
 292. Finelli C, Gugliotta L, Gamberi B, Vianelli N, Visani G, Tura S. Relief of intractable pruritus in polycythemia vera with recombinant interferon alfa. *Am J Hematol* 1993; 43: 316–318.
 293. Taylor PC, Dolan G, Ng JP, Paul B, Collin R, Reilly JT. Efficacy of recombinant interferon-alpha (rIFN-alpha) in polycythaemia vera: a study of 17 patients and an analysis of published data. *Br J Haematol* 1996; 92: 55–59.
 294. Shelley WB, Shelley ED. Aquadynia: noradrenergic pain induced by bathing and responsive to clonidine. *J Am Acad Dermatol* 1998; 38: 357–358.
 295. Wolf R, Krakowski A. Variations in aquagenic pruritus and treatment alternatives. *J Am Acad Dermatol* 1988; 18: 1081–1083.
 296. Steinman HK, Greaves MW. Aquagenic pruritus. *J Am Acad Dermatol* 1985; 13: 91–96.